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Abstract: Background: Improved markers of prognosis are needed to 
stratify patients with early-stage colorectal cancer to refine selection 
of adjuvant therapy. The aim of the present study was to develop a 
biomarker of patient outcome after primary colorectal cancer resection by 
directly analysing scanned conventional haematoxylin and eosin stained 
sections using deep learning. 
Methods: More than 12,000,000 image tiles from 828 patients with 
distinctly good or poor disease outcome were used to train a total of 10 
convolutional neural networks, purpose-built for classifying supersized 
heterogeneous images. A prognostic biomarker integrating the 10 networks 
were determined using 1645 patients with non-distinct outcome. The marker 
was tested on 920 patients with slides prepared in UK, and finally 
independently validated according to a pre-defined protocol in 1122 
patients treated with single-agent capecitabine using slides prepared in 
Norway. The primary outcome was cancer-specific survival. 
Findings: The biomarker provided a hazard ratio for poor vs good 
prognosis of 3·84 (95% confidence interval, 2·72-5·43; p<0·0001) in the 
primary analysis of the validation cohort, and 3·04 (95% confidence 
interval, 2·07-4·47; p<0·0001) after adjusting for established prognostic 
markers significant in univariable analyses of the same cohort; pN stage, 
pT stage, lymphatic invasion, and venous vascular invasion. 
Interpretation: It was possible to develop a clinically useful prognostic 
marker using deep learning allied to digital scanning of conventional 
haematoxylin and eosin stained tumour tissue sections. The assay has been 
extensively evaluated in large, independent patient populations, 
correlates with and outperforms established molecular and morphological 
prognostic markers, and gives consistent results across tumour and nodal 
stage. The biomarker stratified stage II and III patients into 
sufficiently distinct prognostic groups that these potentially could be 
used to guide selection of adjuvant treatment by avoiding therapy in very 
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  45 
Background: Improved markers of prognosis are needed to stratify patients with early-stage 46 
colorectal cancer to refine selection of adjuvant therapy. The aim of the present study was to 47 
develop a biomarker of patient outcome after primary colorectal cancer resection by directly 48 
analysing scanned conventional haematoxylin and eosin stained sections using deep learning. 49 
Methods: More than 12,000,000 image tiles from 828 patients with distinctly good or poor 50 
disease outcome were used to train a total of 10 convolutional neural networks, purpose-built 51 
for classifying supersized heterogeneous images. A prognostic biomarker integrating the 10 52 
networks were determined using 1645 patients with non-distinct outcome. The marker was 53 
tested on 920 patients with slides prepared in UK, and finally independently validated 54 
according to a pre-defined protocol in 1122 patients treated with single-agent capecitabine 55 
using slides prepared in Norway. The primary outcome was cancer-specific survival. 56 
Findings: The biomarker provided a hazard ratio for poor vs good prognosis of 3·84 (95% 57 
confidence interval, 2·72-5·43; p<0·0001) in the primary analysis of the validation cohort, 58 
and 3·04 (95% confidence interval, 2·07-4·47; p<0·0001) after adjusting for established 59 
prognostic markers significant in univariable analyses of the same cohort; pN stage, pT stage, 60 
lymphatic invasion, and venous vascular invasion. 61 
Interpretation: It was possible to develop a clinically useful prognostic marker using deep 62 
learning allied to digital scanning of conventional haematoxylin and eosin stained tumour 63 
tissue sections. The assay has been extensively evaluated in large, independent patient 64 
populations, correlates with and outperforms established molecular and morphological 65 
prognostic markers, and gives consistent results across tumour and nodal stage. The 66 
biomarker stratified stage II and III patients into sufficiently distinct prognostic groups that 67 
these potentially could be used to guide selection of adjuvant treatment by avoiding therapy in 68 
very low risk groups and identifying patients who would benefit from more intensive regimes. 69 
Funding: The Research Council of Norway through its IKTPLUSS Lighthouse program 70 
(grant number 259204, project name DoMore!). 71 
  72 
Research in context 73 
Evidence before this study 74 
Digital image analysis is one of the fields where the recent renaissance of deep learning has 75 
achieved the most impressive results. We searched PubMed on June 12, 2019 without 76 
language or time restrictions, using the terms “deep learning”, “prediction”, “survival”, 77 
“cancer”, and “histology” (full specification of the search criteria is provided in the appendix 78 
p 3). We systematically reviewed the 214 search results, and found 18 original research 79 
studies which applied deep learning to predict patient outcome or related attributes using 80 
histopathology images. 81 
 82 
In 16 studies, the patient outcome was indirectly predicted by identifying attributes known to 83 
correlate with patient outcome, e.g. stromal fraction, mitotic count, or Gleason pattern. Two 84 
studies reported on direct prediction of survival, but neither presented a marker for automatic 85 
prediction of patient outcome from scanned whole-slide sections; one required manual 86 
annotation to locate interesting tissue regions, and the other classified tissue microarray spots. 87 
Perhaps even more importantly, neither of these two studies evaluated their biomarker in 88 
independent cohorts; the performance was instead estimated using cross-validation in the 89 
same cohort as utilised for training, which can easily lead to overoptimistic estimates. 90 
 91 
Added value of the study 92 
We have applied deep learning to develop a biomarker for automatic prediction of cancer-93 
specific survival directly from scanned haematoxylin and eosin stained, formalin-fixed, 94 
paraffin-embedded tumour tissue sections. Independent validation demonstrated that the 95 
biomarker improved prediction of cancer-specific survival by stratifying stage II and III 96 
colorectal cancer patients into distinct prognostic groups, supplementing established 97 
prognostic markers, and outperforming most existing markers in terms of hazard ratios. The 98 
marker could potentially be used to improve selection of adjuvant treatment after resection of 99 
colorectal cancer by identifying patients at very low risk who may have been cured by surgery 100 
alone, as well as patients at high risk who are much more likely to benefit from more 101 
intensive regimes. 102 
 103 
Implications of all the available evidence 104 
It is possible to utilise deep learning to develop biomarkers for automatic prediction of patient 105 
outcome directly from conventional histopathology images. In colorectal cancer, the marker 106 
was found to be a clinically useful prognostic marker in analysis of a large series of patients 107 
who received consistent, modern cancer treatment. 108 
  109 
Introduction 110 
Biomarkers are being used increasingly to match anticancer therapy to specific tumour 111 
genotypes, protein, and RNA expression profiles, usually in patients with advanced disease.
1–3
 112 
One example of this is selection of KRAS-wild-type colorectal cancers (CRCs) for treatment 113 
with epidermal growth factor receptor inhibitors.
4
 However, in the adjuvant setting for CRC, 114 
the primary question is binary, whether to offer treatment at all, and subsequent selection of 115 
drugs, dose, and schedule is predominantly driven by stage rather than by companion 116 
diagnostics. If it were possible to further refine prognostic models, this could allow a more 117 
targeted approach by defining subgroups in which the absolute benefits of adjuvant 118 
chemotherapy are minimal, relative to surgery alone, and at the other end of the spectrum, 119 




More than two decades of adjuvant trials in patients with early-stage CRC using 122 
fluoropyrimidines, in combination with cytotoxic agents like oxaliplatin, have yielded an 123 
improved overall survival of around 3-5% for patients with stage II or IIIA CRC. Many 124 
patients are cured by surgery alone, while around 25% will recur despite adjuvant 125 
chemotherapy. There is likely to be a chemotherapy-associated death rate of 0·5-1%, and 20% 126 
of patients will suffer significant side-effects. The risk-benefit ratio is therefore rather 127 
marginal, but could potentially be much better if it were possible to define subgroups at 128 
higher or lower risk of recurrence and cancer-specific death.
9–12
 129 
Although clinically validated prognostic biomarkers would facilitate adjuvant therapeutic 130 
decisions, very few have been sufficiently robustly validated for routine clinical application. 131 
A case can be made for assessment of mismatch repair (MMR) status,
13,14
 as patients with 132 
MMR-deficient tumours tend to have a good prognosis. We have recently reported that 133 
measurement of tumour cellular DNA content (ploidy) in combination with stromal fraction 134 
can stratify stage II patients into very good, intermediate, and poor prognostic groups.
15
 135 
Interestingly, analysis of driver mutations and RNA signatures has shown them to be 136 
individually weak prognostic markers and unable to guide clinical decision making.
8,14
 137 
Deep learning refers to the class of machine learning methods that make use of successively 138 
more abstract representations of the input data to perform a specific task. These methods use a 139 
training set to learn how these representations should be generated in a manner appropriate for 140 
the given task. In contrast, traditional machine learning utilises handcrafted features to create 141 
representations of the input data that are applied to perform the task. In many applications, 142 
deep learning has been demonstrated to provide superior performance compared to other 143 
machine learning techniques, and it is a growing expectation that deep learning will transform 144 
current medical practice. Especially convolutional neural networks have excelled in many 145 
image interpretation tasks, and could therefore be hypothesised to retrieve additional 146 
information from histopathology images. The aim of the present study was to use deep 147 
learning to analyse conventional whole-slide images (WSIs) in order to develop an automatic 148 
prognostic biomarker for patients resected for primary CRC. The marker was trained using 149 
828 patients with distinct prognosis from four cohorts, fine-tuned using 1645 other patients 150 
from the same four cohorts, and tested on slides prepared at a different laboratory from 920 151 
patients. Finally, the marker was independently validated according to the pre-defined 152 
protocol (appendix pp 52-80) on 1122 patients analysed retrospectively from a trial 153 





Training and Tuning Cohorts 157 
Four different cohorts were utilised for training and tuning to achieve a broad patient 158 
representation and thereby improve the ability to generalise to new cohorts. Three cohorts 159 
were consecutive series of stage I, II or III tumours from CRC patients treated at hospitals 160 
with both rural and urban catchment areas: (i) 160 patients treated 1988-2000 at Akershus 161 
University Hospital, Norway;
17
 (ii) 576 patients treated 1993-2003 at Aker University 162 
Hospital, Norway;
15
 and (iii) 970 patients treated in Gloucester 1988-1996 and included in the 163 
Gloucester Colorectal Cancer Study, UK.
18,19
 The fourth cohort were 767 stage II or III CRC 164 
patients treated at 151 UK hospitals in 2002-2004 and included in the VICTOR trial (ISRCTN 165 
registry number ISRCTN98278138).
20
 Our cohorts included only patients with resectable 166 
tumour, and a formalin-fixed, paraffin-embedded (FFPE) tumour tissue block available for 167 
analysis. 168 
To obtain clear ground-truth, we used as training cohort the 828 patients with so-called 169 
distinct outcome, either good or poor. A patient was assigned to the good outcome group if 170 
aged less than 85 years at surgery, had more than six years follow-up after surgery, and had 171 
no record of recurrence or cancer-specific death. The poor outcome group consisted of those 172 
aged less than 85 years at surgery and suffered cancer-specific death between 100 days 173 
(inclusive) and 2·5 years (exclusive) after surgery. Patients not satisfying either of these group 174 
criteria were defined as having non-distinct outcome, and these 1645 patients were used for 175 
tuning. The protocol specifies additional cohort details, and demographics are summarised in 176 
table 1. 177 
Test Cohort 178 
The test cohort consisted of 920 patients from the Gloucester Colorectal Cancer Study, 179 
UK.
18,19  WSIs were obtained from different FFPE tumour tissue blocks than those used in the 180 
training and tuning cohorts. 181 
Validation Cohort 182 
The validation cohort consisted of 1122 patients from 170 hospitals in seven countries 183 
recruited to the QUASAR 2 trial (ISRCTN registry number ISRCTN45133151).
16
 Inclusion 184 
criteria were age 18 years or older, CRC adenocarcinoma histologically proven to be R0 M0 185 
stage III or high-risk stage II, primary resection 4-10 weeks before randomisation, WHO 186 
performance status score 0 or 1, and life expectancy (with comorbidities, but excluding cancer 187 
risk) of at least five years. See protocol pp 22-25 for exclusion criteria and other details. All 188 
patients received adjuvant therapy, either capecitabine plus bevacizumab or capecitabine 189 
alone, with equal disease-free and overall survival in both trial arms.
16
 190 
Sample Preparation 191 
Slides in VICTOR cohort were prepared in Oxford, UK, while the other slides in the training 192 
and tuning cohorts were prepared at the Institute for Cancer Genetics and Informatics (ICGI), 193 
Norway. Introducing this variation in the development phase was hypothesised to increase the 194 
robustness and generalisability of the trained marker. Slides in the test cohort were prepared 195 
as a part of the routine histopathological examination in Cheltenham, UK, and the 196 
performance in this cohort should thus indicate the prognostic ability when the marker is 197 
assayed at a different laboratory using original slides. Slides in the validation cohort were 198 
prepared at ICGI. All slides were made by staining a three µm FFPE tissue block section with 199 
haematoxylin and eosin (H&E), and a pathologist (MP) ascertained that it contained tumour. 200 
WSIs were acquired at the highest resolution available (referred to as 40x magnification by 201 
the manufacturers) on two scanners, an Aperio AT2 (Leica Biosystems, Germany) and a 202 
NanoZoomer XR (Hamamatsu Photonics, Japan). 203 
Areas with high tumour content were identified using a segmentation network that was trained 204 
on a subset of the training and tuning cohorts (protocol pp 6-10). A WSI with the so-called 205 
40x resolution typically contained an order of 100,000x100,000 pixels, multiple orders of 206 
magnitude larger than images currently feasible for classification by deep learning methods. 207 
To preserve prognostic information contained at high-resolution, WSIs were partitioned into 208 
multiple non-overlapping image regions called tiles at 10x and 40x resolutions, where each 209 
pixel at 40x represents a physical size of approximately 0·24x0·24 µm
2
. Patients without tiles 210 
were excluded. 211 
Classification 212 
Five networks were trained on the 634,564 10x tiles and five networks on the 11,591,555 40x 213 
tiles from the 1652 Aperio AT2 and NanoZoomer XR WSIs in the training cohort with the 214 
patients’ distinct outcomes as ground-truth. All networks were DoMore v1 networks, which 215 
we designed for classifying supersized heterogeneous images. The DoMore v1 network was 216 
built around multiple instance learning and comprised of a MobileNetV2
21
 representation 217 
network, a Noisy-AND pooling function,
22
 and a fully-connected classification network 218 
similar to the one used by Kraus et al
22
 (figure 1). Because of spatial heterogeneity, labelling a 219 
tile with the label of its WSI might be problematic. Instead, the networks were trained on 220 
labelled collections of tiles. A collection contained tiles from a single WSI, which label it 221 
inherits. Collections of tiles were processed by the representation network before the resulting 222 
tile representations were pooled and classified. The entire network was trained end-to-end, i.e. 223 
directly from image to patient outcome, and each training iteration used a batch size of 32 224 
collections with 64 tiles each. This many tiles were possible because we utilised a novel 225 
gradient approximation technique which substantially reduce memory usage during training 226 
(appendix pp 4-6). The Noisy-AND pooling function applied a trained non-linear function on 227 
tile representation averages. This enhances robustness against tiles not representing the 228 
ground-truth, and together with the large number of tiles, alleviates the issues of spatial 229 
heterogeneity. During inference, the network processed all tiles in the WSI. 230 
The networks were trained beyond apparent convergence using TensorFlow 1·10, and a 231 
model was selected from each network training using the performance in the tuning cohort 232 
with the c-index as metric, resulting in five models for each resolution (protocol pp 11-20). 233 
Each of the five models provides a score reflecting the probability of poor outcome, and the 234 
average was defined as the ensemble score. For use in categorical markers, suitable thresholds 235 
for the 10x and the 40x ensemble scores were determined by evaluations in the tuning cohort 236 
to define the ensemble classifiers (protocol pp 20-22). Furthermore, evaluations in the test 237 
cohort indicated that combining 10x and 40x markers might be desirable, and two such 238 
markers were defined, one continuous and one categorical. The continuous DoMore-v1-CRC 239 
score was defined as the average of the 10x and the 40x ensemble scores. The categorical 240 
DoMore-v1-CRC classifier assigned to good prognosis if both ensemble classifiers predicted 241 
good outcome, uncertain if the ensemble classifiers predicted differently, and poor prognosis 242 
if both predicted poor outcome. In a post-hoc analysis, the continuous DoMore-v1-CRC score 243 
was categorised into five risk groups (appendix p 6). 244 
Inception v3, a state-of-the-art convolutional neural network, was trained, tuned, and 245 
evaluated with the same study setup as the DoMore v1 network (protocol pp 11-22), and 246 
tested as a secondary analysis (protocol p 27). While the DoMore-v1-CRC marker was trained 247 
using multiple instance learning, each single tile was labelled with the label of its WSI in 248 
training the Inception v3 marker. The image distortion algorithm and network 249 
hyperparameters were determined independently of the DoMore v1 network in the discovery 250 
phase, resulting in slightly different choices for the Inception v3 network (protocol pp 15-16). 251 
Statistical Analysis 252 
This study conformed to the REMARK guideline
23
 and relevant aspects of the guideline 253 
proposed by Luo et al
24
 (appendix pp 7-8). Primary and secondary analyses were planned in 254 
advance of evaluations in the validation cohort and described in the protocol. 255 
The pre-defined primary analysis for each scanner was univariable cancer-specific survival 256 
(CSS) analysis of the DoMore-v1-CRC classifier; for simplicity, we first present results for 257 
the Aperio AT2 scanner and in a separate paragraph address scanner differences. The 258 
classifier was included as the only variable in a Cox model to compute the hazard ratio (HR) 259 
with 95% confidence interval (CI) of patients with uncertain and poor prognosis relative to 260 
patients with good prognosis. The proportional hazards assumption was found satisfactory 261 
fulfilled using log-log plots (appendix p 26). The Mantel-Cox log-rank test was used to assess 262 
whether the classifier predicted CSS. 263 
Both the classifier and the continuous score were evaluated in multivariable Cox models as 264 
secondary and post-hoc analyses, including markers available at the time of analysis (patients 265 
with at least one missing value were excluded). To calculate classification metrics for 3-year 266 
CSS, patients without event and less than 3-year follow-up were excluded and events after 3 267 
years were ignored. Category-free net reclassification improvement (NRI) was computed 268 
using the Kaplan-Meier estimates of five-year CSS. Two-sided p<0·05 was considered 269 
statistically significant. The confidence level of CIs is 95%. The bias-corrected and 270 
accelerated bootstrap CI were computed for NRIs, c-indices and areas under the curves 271 
(AUCs) using 10,000 bootstrap replicates and an acceleration constant estimated using leave-272 
one-out cross-validation. Time to CSS in the validation cohort was calculated from date of 273 
randomisation to date of cancer-specific death or loss to follow-up. Survival analyses were 274 
carried out in Stata/SE 15·1 (StataCorp, TX). 275 
Role of the funding source 276 
The funders had no role in study design, data collection, data analysis, data interpretation, 277 
writing the report, or the decision to submit the paper for publication. The corresponding 278 
author had full access to all data and the final responsibility to submit for publication. 279 
 280 
Results 281 
The DoMore-v1-CRC classifier was a strong predictor of CSS in the primary analysis of the 282 
validation cohort (HR for uncertain vs good prognosis, 1·89; CI, 1·14-3·15; HR for poor vs 283 
good prognosis, 3·84; CI, 2·72-5·43; figure 2A). The classifier remained strong in 284 
multivariable analysis (HR for uncertain vs good prognosis, 1·56; CI, 0·92-2·65; HR for poor 285 
vs good prognosis, 3·04; CI, 2·07-4·47; table 2) adjusting for established prognostic markers 286 
significant in univariable analyses; pN stage, pT stage, lymphatic invasion, and venous 287 
vascular invasion (appendix p 9). 288 
The sensitivity was 52% (CI, 41%-63%), specificity 78% (CI, 75%-81%), positive predictive 289 
value 19% (CI, 14%-25%), negative predictive value 94% (CI, 92%-96%), and correct 290 
classification rate 76% (CI, 73%-79%) when comparing 3-year CSS to good prognosis vs 291 
uncertain and poor prognosis. Compared to good and uncertain prognosis vs poor prognosis, 292 
the sensitivity was 69% (CI, 58%-78%), specificity 66% (CI, 63%-69%), positive predictive 293 
value 17% (CI, 13%-21%), negative predictive value 96% (CI, 94%-97%), and correct 294 
classification rate 67% (CI, 63%-69%). 295 
The constituents of the DoMore-v1-CRC classifier, the 10x and the 40x ensemble classifiers, 296 
were strong predictors in univariable (appendix p 27) and multivariable analyses (appendix pp 297 
10-11). The ensemble classifiers performed similarly as the best classifiers based on one of 298 
the ten individual models that constituted the ensemble models (appendix pp 12 and 28-29). 299 
The continuous ensemble scores were also strong predictors in univariable (appendix p 9) and 300 
multivariable analyses (appendix pp 13-15). The DoMore-v1-CRC score associated strongly 301 
with the patient outcome (appendix p 30), and provided a c-index of 0·674 (CI, 0·624-0·719; 302 
appendix p 16) in all validation patients and an AUC of 0·713 (CI, 0·624-0·789; appendix p 303 
31) in patients with distinct outcome. The c-index and AUC of the 10x ensemble score were 304 
similar to the ones obtained for the DoMore-v1-CRC score (appendix pp 16 and 31). 305 
The DoMore-v1-CRC classifier was a significant predictor of CSS in stage II (HR for poor vs 306 
good prognosis, 2·71; CI, 1·25-5·86; figure 2C) and stage III (HR for poor vs good prognosis, 307 
4·09; CI, 2·77-6·03; figure 2D), and this was confirmed in multivariable analysis (table 2) and 308 
for the continuous score (appendix pp 9 and 13). The categorical marker identified patient 309 
groups with substantially different CSS in stage IIIB and IIIC (appendix p 32), and was also 310 
significant in pN stages (figures 2C, E, and F) and pT stages (pT1-3 vs pT4; appendix p 33). 311 
The category-free NRI of supplementing substage with the DoMore-v1-CRC class for 312 
prediction of five-year CSS was 61·6% (CI, 43·5%-79·3%); the event-NRI was 3·2% (CI, -313 
13·2%-20·0%), and the non-event-NRI was 58·3% (CI, 52·7%-63·8%). 314 
The DoMore-v1-CRC classifier correlated with a number of factors such as age, pN stage, pT 315 
stage, histological grade, location, tumour sidedness, BRAF mutation, and microsatellite 316 
instability (table 3). Of special interest is the relation to the histopathological grading into 317 
well, moderately, and poorly differentiated tumours. This was further studied in the test 318 
cohort where all gradings were centrally reviewed by one highly experienced pathologist 319 
(NAS).
18,19
 Among 133 tumours characterised as well differentiated, the DoMore-v1-CRC 320 
classifier assigned 101 as good prognosis, 18 as uncertain and 14 as poor prognosis (appendix 321 
p 17). The moderately differentiated tumours were distributed fairly evenly over the DoMore-322 
v1-CRC classes, while among 292 poorly differentiated tumours, the marker assigned 223 as 323 
poor prognosis, 36 as uncertain, and 33 as good prognosis. Thus, the DoMore-v1-CRC class 324 
was clearly associated to tumour differentiation. The large proportion of tumours classified as 325 
moderately differentiated (e.g. 53% [489 of 920] in the test cohort and 75% [846 of 1122] in 326 
the validation cohort) restricts the usefulness of this grading system, but also these patients 327 
could be risk stratified by the DoMore-v1-CRC marker (appendix p 34). 328 
Median processing time per patient for the entire classification pipeline, i.e. from scan to 329 
predicted patient outcome, was 2·8 minutes (interquartile range, 1·8-3·9) in the validation 330 
cohort on a computer with an NVIDIA GeForce RTX 2080 Ti and an Intel Core i7-7700K. 331 
Inception v3 provided a marker of CSS with only slightly worse performance than the 332 
DoMore-v1-CRC classifier (appendix pp 16 and 35-36). 333 
In the test cohort with slides prepared at a different hospital, the classifier provided similar 334 
HRs (appendix p 37) as in the validation cohort (figure 2), supporting that it is robust against 335 
inter-laboratory differences in tissue preparation and staining. 336 
When evaluated using another scanner (NanoZoomer XR), the DoMore-v1-CRC score tended 337 
towards slightly higher values compared to when evaluated using the Aperio AT2 scanner, 338 
resulting in a higher DoMore-v1-CRC class for some patients near the classification 339 
thresholds (appendix p 38). However, the scores correlated strongly (Pearson’s r=0·956; CI, 340 
0·951-0·961), and the classifier provided similar prognostic information with both scanners 341 
(see appendix pp 9, 16, 18-25, and 39-51 for results with NanoZoomer XR). Thus, the 342 
classifier was also a strong predictor of CSS in the primary analysis of the validation cohort 343 
when evaluated on NanoZoomer XR slide images (HR for uncertain vs good prognosis, 2·42; 344 
CI, 1·45-4·03; HR for poor vs good prognosis, 3·39; CI, 2·36-4·87; appendix p 39). 345 
 346 
Discussion 347 
Building on recent developments in machine learning, we have developed a biomarker for 348 
automatic prediction of the outcome of a patient resected for early-stage CRC which directly 349 
analyse standard H&E stained histological sections. To assay the biomarker, one 350 
convolutional neural network first automatically outlines cancerous tissue, and then a second 351 
convolutional neural network stratifies the patients into prognostic categories. In the 352 
validation, the good and poor prognosis groups included nearly 90% of the patients and 353 
differed about 4 times in HR for CSS in univariable analysis and about 3 times in 354 
multivariable analysis. The multivariable result indicated that the new biomarker will be a 355 
useful supplement to the established markers and improve risk stratification. 356 
Deep learning has already been shown to be suitable for detection and delineation of some 357 
tumour types,
25
 and various cancer classifications have been reported.
26
 Recent studies have 358 
suggested that deep learning could be used to develop markers which potentially utilise basic 359 
morphology to predict the outcome of cancer patients, but these findings have not been 360 
validated in independent cohorts.
27,28
 We have not yet seen independently validated markers 361 
for directly predicting the outcome of cancer patients based on histological images. 362 
We derived two markers using the same study setup, but different deep learning techniques. 363 
In training the Inception v3 marker, each tile was labelled with the label of its WSI, while the 364 
DoMore-v1-CRC marker was developed using multiple instance learning to allow training on 365 
tile collections labelled with the label of its WSI. Both markers were strong predictors of CSS, 366 
but the DoMore-v1-CRC marker performed slightly better and was the marker pre-selected 367 
for independent validation in the QUASAR 2 cohort. 368 
Automatic prognostication procedures reduce human intervention, and has the potential to 369 
increase reproducibility of biomarkers. New procedures like the DoMore-v1-CRC markers 370 
may initially be performed as services carried out at specialised laboratories with a high 371 
degree of standardisation of procedure to avoid disparities in sample handling, including the 372 
staining and scanning. Such centralised processing will also facilitate the collection of 373 
information on new procedures and enable improvements in the decision support to 374 
pathologists and clinicians. As an increasing number of laboratories are becoming digitalised, 375 
accompanying decision support systems may include standardisation modules and facilitate a 376 
more rapid spread of the automatic procedures. Moreover, supplemented by increased 377 
robotisation of wet-lab procedures, the higher analytic throughput will allow decisions based 378 
on multiple samples from a tumour. This may reduce the challenge of tumour heterogeneity, 379 
which may be a key to improved accuracy of prognosis. 380 
The DoMore-v1-CRC biomarker correlated with several recognised prognostic factors, 381 
including the histological grading carried out by a specialised pathologist. The classifier 382 
performed better than most other markers in terms of HRs in stage-specific multivariable 383 
analyses, on a par with pN staging. As opposed to the grading system, the classifier had few 384 
patients in the intermediate “uncertain” group. 385 
The DoMore-v1-CRC classifier is technically simple to apply and can be delivered at 386 
pathology laboratories everywhere. Although training the networks was resource demanding, 387 
new patients can be assayed in a few minutes using consumer hardware. 388 
Clinically, the marker will inform discussion with patients with stage II and III CRC on the 389 
pros and cons of different adjuvant treatment options. Although the number of drugs used in 390 
the adjuvant setting is limited to fluoropyrimidines ± oxaliplatin, recent data demonstrate that 391 
three months treatment achieves approximately the same survival outcomes as six months for 392 
the majority of stage III patients, while high risk patients (pT4 and pN2) might benefit from 393 
prolonged therapy.
29,30
 It would be reasonable to hypothesise that stage III patients identified 394 
as poor prognosis by the DoMore-v1-CRC classifier could benefit from prolonged 395 
combination chemotherapy with oxaliplatin, or even consider experimental therapy 396 
combining fluoropyrimidine + oxaliplatin + irinotecan as their high risk of cancer-specific 397 
death should positively skew the risk-benefit ratio of more aggressive treatments (figures 2D 398 
and F). At the other end, stage III patients with DoMore-v1-CRC good prognosis, the great 399 
majority of whom are pN1, have very good survival with single-agent capecitabine (figure 400 
2E), and good prognosis stage II patients have a very high chance of surgical cure, potentially 401 
eliminating the need for adjuvant treatment. 402 
We plan to undertake prospective adjuvant trials stratifying patients into different prognostic 403 
groups using the DoMore-v1-CRC biomarker and randomising patients into observation, low 404 
intensity and high intensity regimes depending on relative risk score.  However, the currently 405 
available data may also be used by clinicians and patients to make joint and more informed 406 
decisions on adjuvant chemotherapy choices, as the proportional reduction in the HRs for 407 
recurrence and death from CRC following adjuvant treatment is remarkably consistent at 20% 408 
across most well-designed clinical trials, thus translating into quite different absolute survival 409 
improvements for low and high risk subgroups. 410 
Limitation of this study include that the DoMore-v1-CRC marker has not yet been tested 411 
prospectively in clinical settings, and although we are planning a clinical trial with 412 
randomisation, we at present only know the outcome of thorough retrospective testing. The 413 
test and validation indicate good transferability between populations, but there are still 414 
challenges related to standardisation, as illustrated by the differences between the tested 415 
scanners. Differences between laboratories may also be seen for sample handling procedures, 416 
and this is why the introduction into the clinic is suggested to be through services performed 417 
at specialised laboratories. A well-known disadvantage of deep learning is its black-box 418 
nature. The DoMore-v1-CRC marker is related to histological grading, but the marker is still 419 
using small-scale features of the histological images with unknown biological correlates. 420 
In summary, it has been possible to develop a clinically useful prognostic marker using deep 421 
learning allied to digital scanning of conventional H&E stained, FFPE tumour tissue sections. 422 
The assay has been extensively evaluated in large, independent patient populations, correlates 423 
with and outperforms established molecular and morphological prognostic markers, gives 424 
consistent results across tumour and nodal stage, and can potentially be used by clinicians to 425 
improve decision making over adjuvant treatment choices. 426 
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Figure Legends 538 
 539 
Figure 1: Pipeline of DoMore-v1-CRC classification 540 
Top: A whole-slide image (WSI) is segmented, and the segmented regions tiled at 40x 541 
resolution and 10x resolution. For each resolution, the five trained models each produce one 542 
score reflecting the probability of poor outcome. The average of those scores is the ensemble 543 
score, one for 10x and one for 40x. If the ensemble score is above a certain threshold, the WSI 544 
is classified as poor prognosis. The DoMore-v1-CRC class is determined by the agreement 545 
between the two ensemble classifications. Bottom: The DoMore v1 network is comprised of a 546 
representation network (MobileNetV2
21
), a pooling function (Noisy-AND
22
), and a simple 547 
fully-connected classification network. All components of the DoMore v1 network involve 548 
trainable parameters, and the entire network is trained end-to-end. All tiles from a WSI are 549 
processed by the representation network one by one, resulting in a collection of tile 550 
representations. The pooling function reduces the representations into two numbers, which are 551 
then processed by the classification network to produce the score outputted by the model. 552 
  553 
Figure 2: Kaplan-Meier analysis of cancer-specific survival by DoMore-v1-CRC class 554 
evaluated on Aperio AT2 slide images in the QUASAR 2 validation cohort 555 
(A) The primary analysis; all patients evaluated with the pre-defined DoMore-v1-CRC 556 
classifier. (B) A post-hoc analysis; all patients evaluated with the DoMore-v1-CRC classifier 557 
variant with five categories. (C) A secondary analysis; stage II (equivalent to pN0) patients 558 
evaluated with the pre-defined DoMore-v1-CRC classifier. (D) A secondary analysis; stage 559 
III patients evaluated with the pre-defined DoMore-v1-CRC classifier. (E) A post-hoc 560 
analysis; pN1 patients evaluated with the pre-defined DoMore-v1-CRC classifier. (F) A post-561 
hoc analysis; pN2 patients evaluated with the pre-defined DoMore-v1-CRC classifier. 562 
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Background: Improved markers of prognosis are needed to stratify patients with early-stage 49 
colorectal cancer to refine selection of adjuvant therapy. The aim of the present study was to 50 
develop a biomarker of patient outcome after primary colorectal cancer resection by directly 51 
analysing scanned conventional haematoxylin and eosin stained sections using deep learning. 52 
Methods: More than 12,000,000 image tiles from 828 patients with distinctly good or poor 53 
disease outcome were used to train a total of 10 convolutional neural networks, purpose-built 54 
for classifying supersized heterogeneous images. A prognostic biomarker integrating the 10 55 
networks were determined using 1645 patients with non-distinct outcome. The marker was 56 
tested on 920 patients with slides prepared in UK, and finally independently validated 57 
according to a pre-defined protocol in 1122 patients treated with single-agent capecitabine 58 
using slides prepared in Norway. The primary outcome was cancer-specific survival. 59 
Findings: The biomarker provided a hazard ratio for poor vs good prognosis of 3·84 (95% 60 
confidence interval, 2·72-5·43; p<0·0001) in the primary analysis of the validation cohort, 61 
and 3·04 (95% confidence interval, 2·07-4·47; p<0·0001) after adjusting for established 62 
prognostic markers significant in univariable analyses of the same cohort; pN stage, pT stage, 63 
lymphatic invasion, and venous vascular invasion. 64 
Interpretation: It was possible to develop a clinically useful prognostic marker using deep 65 
learning allied to digital scanning of conventional haematoxylin and eosin stained tumour 66 
tissue sections. The assay has been extensively evaluated in large, independent patient 67 
populations, correlates with and outperforms established molecular and morphological 68 
prognostic markers, and gives consistent results across tumour and nodal stage. The 69 
biomarker stratified stage II and III patients into sufficiently distinct prognostic groups that 70 
these potentially could be used to guide selection of adjuvant treatment by avoiding therapy in 71 
very low risk groups and identifying patients who would benefit from more intensive regimes. 72 
Funding: The Research Council of Norway through its IKTPLUSS Lighthouse program 73 
(grant number 259204, project name DoMore!). 74 
  75 
Research in context 76 
Evidence before this study 77 
Digital image analysis is one of the fields where the recent renaissance of deep learning has 78 
achieved the most impressive results. We searched PubMed on June 12, 2019 without 79 
language or time restrictions, using the terms “deep learning”, “prediction”, “survival”, 80 
“cancer”, and “histology” (full specification of the search criteria is provided in the appendix 81 
p 3). We systematically reviewed the 214 search results, and found 18 original research 82 
studies which applied deep learning to predict patient outcome or related attributes using 83 
histopathology images. 84 
 85 
In 16 studies, the patient outcome was indirectly predicted by identifying attributes known to 86 
correlate with patient outcome, e.g. stromal fraction, mitotic count, or Gleason pattern. Two 87 
studies reported on direct prediction of survival, but neither presented a marker for automatic 88 
prediction of patient outcome from scanned whole-slide sections; one required manual 89 
annotation to locate interesting tissue regions, and the other classified tissue microarray spots. 90 
Perhaps even more importantly, neither of these two studies evaluated their biomarker in 91 
independent cohorts; the performance was instead estimated using cross-validation in the 92 
same cohort as utilised for training, which can easily lead to overoptimistic estimates. 93 
 94 
Added value of the study 95 
We have applied deep learning to develop a biomarker for automatic prediction of cancer-96 
specific survival directly from scanned haematoxylin and eosin stained, formalin-fixed, 97 
paraffin-embedded tumour tissue sections. Independent validation demonstrated that the 98 
biomarker improved prediction of cancer-specific survival by stratifying stage II and III 99 
colorectal cancer patients into distinct prognostic groups, supplementing established 100 
prognostic markers, and outperforming most existing markers in terms of hazard ratios. The 101 
marker could potentially be used to improve selection of adjuvant treatment after resection of 102 
colorectal cancer by identifying patients at very low risk who may have been cured by surgery 103 
alone, as well as patients at high risk who are much more likely to benefit from more 104 
intensive regimes. 105 
 106 
Implications of all the available evidence 107 
It is possible to utilise deep learning to develop biomarkers for automatic prediction of patient 108 
outcome directly from conventional histopathology images. In colorectal cancer, the marker 109 
was found to be a clinically useful prognostic marker in analysis of a large series of patients 110 
whichwho received consistent, modern cancer treatment. 111 
  112 
Introduction 113 
Biomarkers are being used increasingly to match anticancer therapy to specific tumour 114 
genotypes, protein, and RNA expression profiles, usually in patients with advanced disease.
1–3
 115 
One example of this is selection of KRAS-wild-type colorectal cancers (CRCs) for treatment 116 
with epidermal growth factor receptor inhibitors.
4
 However, in the adjuvant setting for CRC, 117 
the primary question is binary, whether to offer treatment at all, and subsequent selection of 118 
drugs, dose, and schedule is predominantly driven by stage rather than by companion 119 
diagnostics. If it were possible to further refine prognostic models, this could allow a more 120 
targeted approach by defining subgroups in which the absolute benefits of adjuvant 121 
chemotherapy are minimal, relative to surgery alone, and at the other end of the spectrum, 122 




More than two decades of adjuvant trials in patients with early-stage CRC using 125 
fluropyrimidinesfluoropyrimidines, in combination with cytotoxic agents like oxaliplatin, 126 
have yielded an improved overall survival of around 3-5% for patients with stage II or IIIA 127 
CRC. Many patients are cured by surgery alone, while around 25% will recur despite adjuvant 128 
chemotherapy. There is likely to be a chemotherapy-associated death rate of 0.·5-1%, and 129 
20% of patients will suffer significant side-effects. The risk-benefit ratio is therefore rather 130 
marginal, but could potentially be much better if it were possible to define subgroups at 131 
higher or lower risk of recurrence and cancer-specific death.
9–12
 132 
Although clinically validated prognostic biomarkers would facilitate adjuvant therapeutic 133 
decisions, very few have been sufficiently robustly validated for routine clinical application. 134 
A case can be made for assessment of mismatch repair (MMR) status,
13,14
 as patients with 135 
MMR-deficient tumours tend to have a good prognosis. We have recently reported that 136 
measurement of tumour cellular DNA content (ploidy) in combination with stromal fraction 137 
can stratify stage II patients into very good, intermediate, and poor prognostic groups.
15
 138 
Interestingly, analysis of driver mutations and RNA signatures has shown them to be 139 
individually weak prognostic markers and unable to guide clinical decision making.
8,14
 140 
Deep learning supersedes other machine learning techniques in many applications and is 141 
expected torefers to the class of machine learning methods that make use of successively 142 
more abstract representations of the input data to perform a specific task. These methods use a 143 
training set to learn how these representations should be generated in a manner appropriate for 144 
the given task. In contrast, traditional machine learning utilises handcrafted features to create 145 
representations of the input data that are applied to perform the task. In many applications, 146 
deep learning has been demonstrated to provide superior performance compared to other 147 
machine learning techniques, and it is a growing expectation that deep learning will transform 148 
current medical practice. Especially convolutional neural networks have excelled in many 149 
image interpretation tasks, and could therefore be hypothesised to retrieve additional 150 
information from pathologicalhistopathology images. The aim of the present study was to use 151 
deep learning to analyse conventional whole-slide images (WSIs) in order to develop an 152 
automatic prognostic biomarker for patients resected for primary CRC. The marker was 153 
trained using 828 patients with distinct prognosis from four cohorts, fine-tuned using 1645 154 
other patients from the same four cohorts, and tested on slides prepared at a different 155 
laboratory from 920 patients. Finally, the marker was independently validated according to 156 
the pre-defined protocol (appendix pp 52-80) on 1122 patients analysed retrospectively from a 157 





Training and Tuning Cohorts 161 
Four different cohorts were utilised for training and tuning to achieve a broad patient 162 
representation and thereby improve the ability to generalise to new cohorts. Three cohorts 163 
were consecutive series of stage I, II or III tumours from CRC patients treated at hospitals 164 
with both rural and urban catchment areas: (i) 160 patients treated 1988-2000 at Akershus 165 
University Hospital, Norway;
17
 (ii) 576 patients treated 1993-2003 at Aker University 166 
Hospital, Norway;
15
 and (iii) 970 patients treated in Gloucester 1988-1996 and included in the 167 




. The fourth cohort were 767 stage II or III 168 
CRC patients treated at 151 UK hospitals in 2002-2004 and included in the VICTOR trial 169 
(ISRCTN registry number ISRCTN98278138).
20
 Our cohorts included only patients with 170 
resectable tumour, and a formalin-fixed, paraffin-embedded (FFPE) tumour tissue block 171 
available for analysis. 172 
To obtain clear ground-truth, we used as training cohort the 828 patients with so-called 173 
distinct outcome, either good or poor. A patient was assigned to the good outcome group if 174 
aged less than 85 years at surgery, had more than six years follow-up after surgery, and had 175 
no record of recurrence or cancer-specific death. The poor outcome group consisted of those 176 
aged less than 85 years at surgery and suffered cancer-specific death between 100 days 177 
(inclusive) and 2·5 years (exclusive) after surgery. Patients not satisfying either of these group 178 
criteria were defined as having non-distinct outcome, and these 1645 patients were used for 179 
tuning. The protocol specifies additional cohort details, and demographics are summarised in 180 
table 1. 181 
Test Cohort 182 





.  WSIs were obtained from different FFPE tumour tissue blocks than those used 184 
in the training and tuning cohorts. 185 
Validation Cohort 186 
The validation cohort consisted of 1122 patients from 170 hospitals in seven countries 187 
recruited to the QUASAR 2 trial (ISRCTN registry number ISRCTN45133151).
16
 Inclusion 188 
criteria were age 18 years or older, CRC adenocarcinoma histologically proven to be R0 M0 189 
stage III or high-risk stage II, primary resection 4-10 weeks before randomisation, WHO 190 
performance status score 0 or 1, and life expectancy (with comorbidities, but excluding cancer 191 
risk) of at least five years. See protocol pp 22-25 for exclusion criteria and other details. All 192 
patients received adjuvant therapy, either capecitabine plus bevacizumab or capecitabine 193 
alone, with equal disease-free and overall survival in both trial arms.
16
 194 
Sample Preparation 195 
Slides in VICTOR cohort were prepared in Oxford, UK, while the other slides in the training 196 
and tuning cohorts were prepared at the Institute for Cancer Genetics and Informatics (ICGI), 197 
Norway. Introducing this variation in the development phase was hypothesised to increase the 198 
robustness and generalisability of the trained marker. Slides in the test cohort were prepared 199 
as a part of the routine histopathological examination in Cheltenham, UK, and the 200 
performance in this cohort should thus indicate the prognostic ability when the marker is 201 
assayed at a different laboratory using original slides. Slides in the validation cohort were 202 
prepared at ICGI. All slides were made by staining a three µm FFPE tissue block section with 203 
haematoxylin and eosin (H&E), and a pathologist (MP) ascertained that it contained tumour. 204 
WSIs were acquired at the highest resolution available (referred to as 40x magnification by 205 
the manufacturers) on two scanners, an Aperio AT2 (Leica Biosystems, Germany) and a 206 
NanoZoomer XR (Hamamatsu Photonics, Japan). 207 
Areas with high tumour content were identified using a segmentation network that werewas 208 
trained on a subset of the training and tuning cohorts (protocol pp 6-10). A WSI with the so-209 
called 40x resolution typically contained an order of 100,000x100,000 pixels, multiple orders 210 
of magnitude larger than images currently feasible for classification by deep learning 211 
methods. To preserve prognostic information contained at high-resolution, WSIs were 212 
partitioned into multiple non-overlapping image regions called tiles at 10x and 40x 213 
resolutions, where each pixel at 40x represents a physical size of approximately 0·24x0·24 214 
µm
2
. Patients without tiles were excluded. 215 
Classification 216 
Five networks were trained on the 634,564 10x tiles and five networks on the 11,591,555 40x 217 
tiles from the 1652 Aperio AT2 and NanoZoomer XR WSIs in the training cohort with the 218 
patients’ distinct outcomes as ground-truth. All networks were DoMore v1 networks, which 219 
we designed for classifying supersized heterogeneous images. The DoMore v1 network was 220 
built around multiple instance learning and comprised of a MobileNetV2
21
 representation 221 
network, a Noisy-AND pooling function,
22
 and a fully-connected classification network 222 
similar to the one used by Kraus et al
22
 (figure 1). Because of spatial heterogeneity, labelling a 223 
tile with the label of its WSI might be problematic. Instead, the networks were trained on 224 
labelled collections of tiles. A collection contained tiles from a single WSI, which label it 225 
inherits. Collections of tiles were processed by the representation network before the resulting 226 
tile representations were pooled and classified. The entire network was trained end-to-end, i.e. 227 
directly from image to patient outcome, and each training iteration used a batch size of 32 228 
collections with 64 tiles each. This many tiles were possible because we utilised a novel 229 
gradient approximation technique which substantially reduce memory usage during training 230 
(appendix pp 4-6). The Noisy-AND pooling function applied a trained non-linear function on 231 
tile representation averages. This enhanceenhances robustness against tiles not representing 232 
the ground-truth, and together with the large number of tiles, alleviates the issues of spatial 233 
heterogeneity. During inference, the network processed all tiles in the WSI. 234 
The networks were trained beyond apparent convergence using TensorFlow 1·10, and a 235 
model was selected from each network training using the performance in the tuning cohort 236 
with the c-index as metric, resulting in five models for each resolution (protocol pp 11-20). 237 
Each of the five models provides a score reflecting the probability of poor outcome, and the 238 
average was defined as the ensemble score. For use in categorical markers, suitable thresholds 239 
for the 10x and the 40x ensemble scores were determined by evaluations in the tuning cohort 240 
to define the ensemble classifiers (protocol pp 20-22). Furthermore, evaluations in the test 241 
cohort indicated that combining 10x and 40x markers might be desirable, and two such 242 
markers were defined, one continuous and one categorical. The continuous DoMore-v1-CRC 243 
score was defined as the average of the 10x and the 40x ensemble scores. The categorical 244 
DoMore-v1-CRC classifier assigned to good prognosis if both ensemble classifiers predicted 245 
good outcome, uncertain if the ensemble classifiers predicted differently, and poor prognosis 246 
if both predicted poor outcome. In a post-hoc analysis, the continuous DoMore-v1-CRC score 247 
was categorised into five risk groups (appendix p 6). 248 
Inception v3, a state-of-the-art convolutional neural network, was trained, tuned, and 249 
evaluated with the same study setup as the DoMore v1 network (protocol pp 11-22), and 250 
tested as a secondary analysis (protocol p 27). While the DoMore-v1-CRC marker was trained 251 
using multiple instance learning, each single tile was labelled with the label of its WSI in 252 
training the Inception v3 marker. The image distortion algorithm and network 253 
hyperparameters were determined independently of the DoMore v1 network in the discovery 254 
phase, resulting in slightly different choices for the Inception v3 network (protocol pp 15-16). 255 
Statistical Analysis 256 
This study conformed to the REMARK guideline
23
 and relevant aspects of the guideline 257 
proposed by Luo et al
24
 (appendix pp 7-8). Primary and secondary analyses were planned in 258 
advance of evaluations in the validation cohort and described in the protocol. 259 
The pre-defined primary analysis for each scanner was univariable cancer-specific survival 260 
(CSS) analysis of the DoMore-v1-CRC classifier; for simplicity, we first present results for 261 
the Aperio AT2 scanner and in a separate paragraph address scanner differences. The 262 
classifier was included as the only variable in a Cox model to compute the hazard ratio (HR) 263 
with 95% confidence interval (CI) of patients with uncertain and poor prognosis relative to 264 
patients with good prognosis. The proportional hazards assumption was found satisfactory 265 
fulfilled using log-log plots (appendix p 26). The Mantel-Cox log-rank test was used to assess 266 
whether the classifier predicted CSS. 267 
Both the classifier and the continuous score were evaluated in multivariable Cox models as 268 
secondary and post-hoc analyses, including markers available at the time of analysis (patients 269 
with at least one missing value were excluded). To calculate classification metrics for 3-year 270 
CSS, patients without event and less than 3-year follow-up were excluded and events after 3 271 
years were ignored. Category-free net reclassification improvement (NRI) was computed 272 
using the Kaplan-Meier estimates of five-year CSS. Two-sided p<0·05 was considered 273 
statistically significant. The confidence level of CIs is 95%. The bias-corrected and 274 
accelerated bootstrap CI were computed for NRIs, c-indices and areas under the curves 275 
(AUCs) using 10,000 bootstrap replicates and an acceleration constant estimated using leave-276 
one-out cross-validation. Time to CSS in the validation cohort was calculated from date of 277 
randomisation to date of cancer-specific death or loss to follow-up. Survival analyses were 278 
carried out in Stata/SE 15·1 (StataCorp, TX). 279 
Role of the funding source 280 
The funders had no role in study design, data collection, data analysis, data interpretation, 281 
writing the report, or the decision to submit the paper for publication. The corresponding 282 
author had full access to all data and the final responsibility to submit for publication. 283 
 284 
Results 285 
The DoMore-v1-CRC classifier was a strong predictor of CSS in the primary analysis of the 286 
validation cohort (HR for uncertain vs good prognosis, 1·89; CI, 1·14-3·15; HR for poor vs 287 
good prognosis, 3·84; CI, 2·72-5·43; figure 2A). The classifier remained strong in 288 
multivariable analysis (HR for uncertain vs good prognosis, 1·56; CI, 0·92-2·65; HR for poor 289 
vs good prognosis, 3·04; CI, 2·07-4·47; table 2) adjusting for established prognostic markers 290 
significant in univariable analyses; pN stage, pT stage, lymphatic invasion, and venous 291 
vascular invasion (appendix p 9). 292 
The sensitivity was 52% (CI, 41%-63%), specificity 78% (CI, 75%-81%), positive predictive 293 
value 19% (CI, 14%-25%), negative predictive value 94% (CI, 92%-96%), and correct 294 
classification rate 76% (CI, 73%-79%) when comparing 3-year CSS to good prognosis vs 295 
uncertain and poor prognosis. Compared to good and uncertain prognosis vs poor prognosis, 296 
the sensitivity was 69% (CI, 58%-78%), specificity 66% (CI, 63%-69%), positive predictive 297 
value 17% (CI, 13%-21%), negative predictive value 96% (CI, 94%-97%), and correct 298 
classification rate 67% (CI, 63%-69%). 299 
The constituents of the DoMore-v1-CRC classifier, the 10x and the 40x ensemble classifiers, 300 
were strong predictors in univariable (appendix p 27) and multivariable analyses (appendix pp 301 
10-11). The ensemble classifiers performed similarly as the best classifiers based on one of 302 
the ten individual models that constituted the ensemble models (appendix pp 12 and 28-29). 303 
The continuous ensemble scores were also strong predictors in univariable (appendix p 9) and 304 
multivariable analyses (appendix pp 13-15). The DoMore-v1-CRC score associated strongly 305 
with the patient outcome (appendix p 30), and provided a c-index of 0·674 (CI, 0·624-0·719; 306 
appendix p 16) in all validation patients and an AUC of 0·713 (CI, 0·624-0·789; appendix p 307 
31) in patients with distinct outcome. The c-index and AUC of the 10x ensemble score were 308 
similar to the ones obtained for the DoMore-v1-CRC score (appendix pp 16 and 31). 309 
The DoMore-v1-CRC classifier was a significant predictor of CSS in stage II (HR for poor vs 310 
good prognosis, 2·71; CI, 1·25-5·86; figure 2C) and stage III (HR for poor vs good prognosis, 311 
4·09; CI, 2·77-6·03; figure 2D), and this was confirmed in multivariable analysis (table 2) and 312 
for the continuous score (appendix pp 9 and 13). The categorical marker identified patient 313 
groups with substantially different CSS in stage IIIB and IIIC (appendix p 32), and was also 314 
significant in pN stages (figures 2C, E, and F) and pT stages (pT1-3 vs pT4; appendix p 33). 315 
The category-free NRI of supplementing substage with the DoMore-v1-CRC class for 316 
prediction of five-year CSS was 61·6% (CI, 43·5%-79·3%); the event-NRI was 3·2% (CI, -317 
13·2%-20·0%), and the non-event-NRI was 58·3% (CI, 52·7%-63·8%). 318 
The DoMore-v1-CRC classifier correlated with a number of factors such as age, pN stage, pT 319 
stage, histological grade, location, tumour sidedness, BRAF mutation, and microsatellite 320 
instability (table 3). Of special interest is the relation to the pathologicalhistopathological 321 
grading into well, moderately, and poorly differentiated tumours. This was further studied in 322 
the test cohort where all gradings were centrally reviewed by one highly experienced 323 
pathologist (NAS).
18,19
 Among 133 tumours characterised as well differentiated, the DoMore-324 
v1-CRC classifier assigned 101 as good prognosis, 18 as uncertain and 14 as poor prognosis 325 
(appendix p 17). The moderately differentiated tumours were distributed fairly evenly over 326 
the DoMore-v1-CRC classes, while among 292 poorly differentiated tumours, the marker 327 
assigned 223 as poor prognosis, 36 as uncertain, and 33 as good prognosis. Thus, the 328 
DoMore-v1-CRC class was clearly associated to tumour differentiation. The large proportion 329 
of tumours classified as moderately differentiated (e.g. 53% [489 of 920] in the test cohort 330 
and 75% [846 of 1122] in the validation cohort) restricts the usefulness of this grading 331 
system, but also these patients could be risk stratified by the DoMore-v1-CRC marker 332 
(appendix p 34). 333 
Median processing time per patient for the entire classification pipeline, i.e. from scan to 334 
predicted patient outcome, was 2.·8 minutes (interquartile range, 1.·8-3.·9) in the validation 335 
cohort on a computer with an NVIDIA GeForce RTX 2080 Ti and an Intel Core i7-7700K. 336 
Inception v3, a state-of-the-art convolutional neural network, was trained, tuned, and 337 
evaluated with the same study setup as the DoMore v1 network (protocol pp 11-22), and 338 
Inception v3 provided a marker of CSS with only slightly worse performance than the 339 
DoMore-v1-CRC classifier (appendix pp 16 and 35-36). 340 
In the test cohort with slides prepared at a different hospital, the classifier provided similar 341 
HRs (appendix p 37) as in the validation cohort (figure 2), supporting that it is robust against 342 
inter-laboratory differences in tissue preparation and staining. 343 
When evaluated using another scanner (NanoZoomer XR), the DoMore-v1-CRC score tended 344 
towards slightly higher values compared to when evaluated using the Aperio AT2 scanner, 345 
resulting in a higher DoMore-v1-CRC class for some patients near the classification 346 
thresholds (appendix p 38). However, the scores correlated strongly (Pearson’s r=0·956; CI, 347 
0·951-0·961), and the classifier provided similar prognostic information with both scanners 348 
(see appendix pp 9, 16, 18-25, and 39-51 for results with NanoZoomer XR). Thus, the 349 
classifier was also a strong predictor of CSS in the primary analysis of the validation cohort 350 
when evaluated on NanoZoomer XR slide images (HR for uncertain vs good prognosis, 2·42; 351 
CI, 1·45-4·03; HR for poor vs good prognosis, 3·39; CI, 2·36-4·87; appendix p 39). 352 
 353 
Discussion 354 
Building on recent developments in machine learning, we have developed a biomarker for 355 
automatic prediction of the outcome of a patient resected for early-stage CRC which directly 356 
analyse standard H&E stained histological sections. To assay the biomarker, one 357 
convolutional neural network first automatically outlines cancerous tissue, and then a second 358 
convolutional neural network stratifies the patients into prognostic categories. In the 359 
validation, the good and poor prognosis groups included nearly 90% of the patients and 360 
differed about 4 times in HR for CSS in univariable analysis and about 3 times in 361 
multivariable analysis. The multivariable result indicated that the new biomarker will be a 362 
useful supplement to the established markers and improve risk stratification. 363 
Deep learning has already been shown to be suitable for detection and delineation of some 364 
tumour types,
25
 and various cancer classifications have been reported.
26
 Recent studies have 365 
suggested that deep learning could be used to develop markers which potentially utilise basic 366 
morphology to predict the outcome of cancer patients, but these findings have not been 367 
validated in independent cohorts.
27,28
 We have not yet seen independently validated markers 368 
for directly predicting the outcome of cancer patients based on histological images. 369 
We derived two markers using the same study setup, but different deep learning techniques. 370 
In training the Inception v3 marker, each tile was labelled with the label of its WSI, while the 371 
DoMore-v1-CRC marker was developed using multiple instance learning to allow training on 372 
tile collections labelled with the label of its WSI. Both markers were strong predictors of CSS, 373 
but the DoMore-v1-CRC marker performed slightly better and was the marker pre-selected 374 
for independent validation in the QUASAR 2 cohort. 375 
Automatic prognostication procedures reduce human intervention, and has the potential to 376 
increase reproducibility of biomarkers. New procedures like the DoMore-v1-CRC markers 377 
may initially be performed as services carried out at specialised laboratories with a high 378 
degree of standardisation of procedure to avoid disparities in sample handling, including in 379 
the staining and scanning. Such centralised processing will also facilitate the collection of 380 
information on new procedures and enable improvements in the decision support to 381 
pathologists and clinicians. As an increasing number of laboratories are becoming digitalised, 382 
accompanying decision support systems may include standardisation modules and facilitate a 383 
more rapid spread of the automatic procedures. Moreover, supplemented by increased 384 
robotisation of wet-lab procedures, the higher analytic throughput will allow decisions based 385 
on multiple samples from a tumour. This may reduce the challenge of tumour heterogeneity, 386 
which may be a key to improved accuracy of prognosis. 387 
The DoMore-v1-CRC biomarker correlated with several recognised prognostic factors, 388 
including the histological grading carried out by a specialised pathologist. The classifier 389 
performed better than most other markers in terms of HRs in stage-specific multivariable 390 
analyses, on a par with pN staging. As opposed to the grading system, the classifier had few 391 
patients in the intermediate “uncertain” group. 392 
The DoMore-v1-CRC classifier is technically simple to apply and can be delivered at 393 
pathology laboratories everywhere. Although training the networks was resource demanding, 394 
new patients can be assayed in a few minutes using consumer hardware. 395 
Clinically, the marker will inform discussion with patients with stage II and III CRC on the 396 
pros and cons of different adjuvant treatment options. Although the number of drugs used in 397 
the adjuvant setting is limited to fluoropyrimidines ± oxaliplatin, recent data demonstrate that 398 
three months treatment achieves approximately the same survival outcomes as six months for 399 
the majority of stage III patients, while high risk patients (pT4 and pN2) might benefit from 400 
prolonged therapy.
29,30
 It would be reasonable to hypothesise that stage III patients identified 401 
as poor prognosis by the DoMore-v1-CRC classifier could benefit from prolonged 402 
combination chemotherapy with oxaliplatin, or even consider experimental therapy 403 
combining fluropyrimidinefluoropyrimidine + oxaliplatin + irinotecan as their high risk of 404 
cancer-specific death should positively skew the risk-benefit ratio of more aggressive 405 
treatments (figures 2D and F). At the other end, stage III patients with DoMore-v1-CRC good 406 
prognosis, the great majority of whom are pN1, have excellentvery good survival with single-407 
agent capecitabine (figure 2E), and good prognosis stage II patients have a very high chance 408 
of surgical cure, potentially eliminating the need for adjuvant treatment. 409 
We plan to undertake prospective adjuvant trials stratifying patients into different prognostic 410 
groups using the DoMore-v1-CRC biomarker and randomising patients into observation, low 411 
intensity and high intensity regimes depending on relative risk score.  However, the currently 412 
available data may also be used by clinicians and patients to make joint and more informed 413 
decisions on adjuvant chemotherapy choices, as the proportional reduction in the HRs for 414 
recurrence and death from CRC following adjuvant treatment is remarkably consistent at 20% 415 
across most well-designed clinical trials, thus translating into quite different absolute survival 416 
improvements for low and high risk subgroups. 417 
Limitation of this study include that the DoMore-v1-CRC marker has not yet been tested 418 
prospectively in clinical settings, and although we are planning a clinical trial with 419 
randomisation, we at present only know the outcome of thorough retrospective testing. The 420 
test and validation indicate good transferability between populations, but there are still 421 
challenges related to standardisation, as illustrated by the differences between the tested 422 
scanners. Differences between laboratories may also be seen for sample handling procedures, 423 
and this is why the introduction into the clinic is suggested to be through services performed 424 
at specialised laboratories. A well-known disadvantage of deep learning is its black-box 425 
nature. The DoMore-v1-CRC marker is related to histological grading, but the marker is still 426 
using small-scale features of the histological images with unknown biological correlates. 427 
In summary, it has been possible to develop a clinically useful prognostic marker using deep 428 
learning allied to digital scanning of conventional H&E stained, FFPE tumour tissue sections. 429 
The assay has been extensively evaluated in large, independent patient populations, correlates 430 
with and outperforms established molecular and morphological prognostic markers, gives 431 
consistent results across tumour and nodal stage, and can potentially be used by clinicians to 432 
improve decision making over adjuvant treatment choices. 433 
 434 
Contributors 435 
OJS, SDR, AK, TSH, KL, FA, DJK, and HED designed the study. HAA, JAN, AN, NAS, IT, 436 
RK, MN, and DJK collected the samples and acquired the image data. MP, INF, ED, DNC, 437 
AN, NAS, IT, RK, MN, and DJK provided clinical/pathological data and interpretations. OJS, 438 
SDR, and JM performed the machine learning. AK performed the statistical analyses. OJS, 439 
SDR, AK, TSH, KL, DJK, and HED interpreted the data and analyses. All authors vouch for 440 
the data, analyses, and interpretations. OJS, SDR, AK, TSH, KL, DJK, and HED wrote the 441 
first draft of the manuscript, and all authors reviewed, contributed to, and approved the 442 
manuscript. 443 
 444 
Declaration of interests 445 
OJS, TSH, KL, JM, and HED report filing of a patent application entitled “Histological image 446 
analysis” with International Patent Application Number PCT/EP2018/080828. The University 447 
of Oxford (to DJK) received educational grants from Roche to support the QUASAR 2 trial 448 




We thank Akershus University Hospital for access to their patient material, National Institute 453 
for Health Research for funding support to Marco Novelli through Biomedical Research 454 
Centres, Paul Callaghan for animating the appendix video, Marian Seiergren for creating 455 
figure 1 and assembling figure 2, the laboratory and technical personnel at the Institute for 456 
Cancer Genetics and Informatics for assistance, and the reviewers for valuable suggestions. 457 
We also would like to thank the participating centres in the VICTOR and QUASAR 2 trials as 458 
well as the staff at Akershus University Hospital, Aker University Hospital and the 459 
Gloucestershire hospitals contributing to the Gloucester Colorectal Cancer Study, and last, but 460 
not least all participating patients for making this study possible. 461 
  462 
References 463 
1. La Thangue NB, Kerr DJ. Predictive biomarkers: a paradigm shift towards 464 
personalized cancer medicine. Nat Rev Clin Oncol 2011; 8: 587–96. 465 
2. Van Allen EM, Wagle N, Stojanov P, et al. Whole-exome sequencing and clinical 466 
interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer 467 
medicine. Nat Med 2014; 20: 682–88. 468 
3. Moscow JA, Fojo T, Schilsky RL. The evidence framework for precision cancer 469 
medicine. Nat Rev Clin Oncol 2018; 15: 183–92. 470 
4. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from 471 
cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757–65. 472 
5. Kerr DJ, Shi Y. Biological markers: Tailoring treatment and trials to prognosis. Nat 473 
Rev Clin Oncol 2013; 10: 429–30. 474 
6. Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and 475 
BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal 476 
cancer. J Clin Oncol 2011; 29: 1261–70. 477 
7. Salazar R, Roepman P, Capella G, et al. Gene expression signature to improve 478 
prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011; 29: 17–24. 479 
8. Gray RG, Quirke P, Handley K, et al. Validation study of a quantitative multigene 480 
reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in 481 
patients with stage II colon cancer. J Clin Oncol 2011; 29: 4611–19. 482 
9. QUASAR Collaborative Group. Comparison of fluorouracil with additional 483 
levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: 484 
a randomised trial. Lancet 2000; 355: 1588–96. 485 
10. QUASAR Collaborative Group. Adjuvant chemotherapy versus observation in 486 
patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020–29. 487 
11. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, 488 
fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the 489 
MOSAIC trial. J Clin Oncol 2009; 27: 3109–16. 490 
12. Andre T, de Gramont A, Vernerey D, et al. Adjuvant Fluorouracil, Leucovorin, and 491 
Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes 492 
According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin 493 
Oncol 2015; 33: 4176–87. 494 
13. Sinicrope FA. DNA mismatch repair and adjuvant chemotherapy in sporadic colon 495 
cancer. Nat Rev Clin Oncol 2010; 7: 174–77. 496 
14. Mouradov D, Domingo E, Gibbs P, et al. Survival in stage II/III colorectal cancer is 497 
independently predicted by chromosomal and microsatellite instability, but not by specific 498 
driver mutations. Am J Gastroenterol 2013; 108: 1785–93. 499 
15. Danielsen HE, Hveem TS, Domingo E, et al. Prognostic markers for colorectal cancer: 500 
estimating ploidy and stroma. Ann Oncol 2018; 29: 616–23. 501 
16. Kerr RS, Love S, Segelov E, et al. Adjuvant capecitabine plus bevacizumab versus 502 
capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised 503 
phase 3 trial. Lancet Oncol 2016; 17: 1543–57. 504 
17. Bondi J, Husdal A, Bukholm G, Nesland JM, Bakka A, Bukholm IR. Expression and 505 
gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in 506 
colon adenocarcinomas and correlation with patient outcome. J Clin Pathol 2005; 58: 509–14. 507 
18. Petersen VC, Baxter KJ, Love SB, Shepherd NA. Identification of objective 508 
pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 509 
2002; 51: 65–69. 510 
19. Mitchard JR, Love SB, Baxter KJ, Shepherd NA. How important is peritoneal 511 
involvement in rectal cancer? A prospective study of 331 cases. Histopathology 2010; 57: 512 
671–79. 513 
20. Midgley RS, McConkey CC, Johnstone EC, et al. Phase III randomized trial assessing 514 
rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin 515 
Oncol 2010; 28: 4575–80. 516 
21. Sandler M, Howard A, Zhu M, Zhmoginov A, Chen L. MobileNetV2: Inverted 517 
Residuals and Linear Bottlenecks. 2018 IEEE/CVF Conference on Computer Vision and 518 
Pattern Recognition 2018: 4510–20. 519 
22. Kraus OZ, Ba JL, Frey BJ. Classifying and segmenting microscopy images with deep 520 
multiple instance learning. Bioinformatics 2016; 32: i52–i59. 521 
23. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for 522 
tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med 2012; 523 
10: 51. 524 
24. Luo W, Phung D, Tran T, et al. Guidelines for Developing and Reporting Machine 525 
Learning Predictive Models in Biomedical Research: A Multidisciplinary View. J Med 526 
Internet Res 2016; 18: e323. 527 
25. Ehteshami Bejnordi B, Veta M, Johannes van Diest P, et al. Diagnostic Assessment of 528 
Deep Learning Algorithms for Detection of Lymph Node Metastases in Women With Breast 529 
Cancer. JAMA 2017; 318: 2199–210. 530 
26. Coudray N, Ocampo PS, Sakellaropoulos T, et al. Classification and mutation 531 
prediction from non-small cell lung cancer histopathology images using deep learning. Nat 532 
Med 2018; 24: 1559–67. 533 
27. Bychkov D, Linder N, Turkki R, et al. Deep learning based tissue analysis predicts 534 
outcome in colorectal cancer. Sci Rep 2018; 8: 3395. 535 
28. Mobadersany P, Yousefi S, Amgad M, et al. Predicting cancer outcomes from 536 
histology and genomics using convolutional networks. Proc Natl Acad Sci U S A 2018; 115: 537 
E2970–E79. 538 
29. Grothey A, Sobrero AF, Shields AF, et al. Duration of Adjuvant Chemotherapy for 539 
Stage III Colon Cancer. N Engl J Med 2018; 378: 1177–88. 540 
30. Iveson TJ, Kerr RS, Saunders MP, et al. 3 versus 6 months of adjuvant oxaliplatin-541 
fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, 542 
randomised, phase 3, non-inferiority trial. Lancet Oncol 2018; 19: 562–78. 543 
 544 
 545 
  546 
Figure Legends 547 
 548 
Figure 1: Pipeline of DoMore-v1-CRC classification 549 
Top: A whole-slide image (WSI) is segmented, and the segmented regions tiled at 40x 550 
resolution and 10x resolution. For each resolution, the five trained models each produce one 551 
score reflecting the probability of poor outcome. The average of those scores is the ensemble 552 
score, one for 10x and one for 40x. If the ensemble score is above a certain threshold, the WSI 553 
is classified as poor prognosis. The DoMore-v1-CRC class is determined by the agreement 554 
between the two ensemble classifications. Bottom: The DoMore v1 network is comprised of a 555 
representation network (MobileNetV2
21
), a pooling function (Noisy-AND
22
), and a simple 556 
fully-connected classification network. All components of the DoMore v1 network involve 557 
trainable parameters, and the entire network is trained end-to-end. All tiles from a WSI are 558 
processed by the representation network one by one, resulting in a collection of tile 559 
representations. The pooling function reduces the representations into two numbers, which are 560 
then processed by the classification network to produce the score outputted by the model. 561 
  562 
Figure 2: Kaplan-Meier analysis of cancer-specific survival by DoMore-v1-CRC class 563 
evaluated on Aperio AT2 slide images in the QUASAR 2 validation cohort 564 
(A) The primary analysis; all patients evaluated with the pre-defined DoMore-v1-CRC 565 
classifier. (B) A post-hoc analysis; all patients evaluated with the DoMore-v1-CRC classifier 566 
variant with five categories. (C) A secondary analysis; stage II (equivalent to pN0) patients 567 
evaluated with the pre-defined DoMore-v1-CRC classifier. (D) A secondary analysis; stage 568 
III patients evaluated with the pre-defined DoMore-v1-CRC classifier. (E) A post-hoc 569 
analysis; pN1 patients evaluated with the pre-defined DoMore-v1-CRC classifier. (F) A post-570 
hoc analysis; pN2 patients evaluated with the pre-defined DoMore-v1-CRC classifier. 571 
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*Reply to Reviewers Comments
THELANCET-D-19-03766R1: Response to comments Page 2 of 13 
1. Please indicate after each of the reviewers' points the text changes which have been made 
(if any) and the line number on the revised manuscript at which your change can be found. 
[Line numbers can be added to your word document using the 'page layout' tab. Please select 
continuous numbers.] 
 
Response: In the responses to the editorial points and reviewers’ comments, the text 
changes have been indicated by the line numbers on the second revision of the 
manuscript draft. 
 
2. When interpreting editorial points made by reviewers, please remember we will edit the 
final manuscript if accepted. 
 
Response: We understand that the manuscript will be edited if accepted.  
 
3. Please indicate any authors who are full professors. 
 
Response: The following authors are full professors: Knut Liestøl, Fritz Albregtsen, 
Inger Nina Farstad, Arild Nesbakken, Neil A. Shepherd, Ian Tomlinson, Rachel Kerr, 
Marco Novelli, David J. Kerr, and Håvard E. Danielsen. The professors are indicated by 
“Prof.” in the author list (see lines 4-10). 
 
4. Please list the highest degree for each author (one degree only, please). 
 
Response: Only the single highest degree for each author has been listed in the author 
list (see lines 4-10). 
 
5. Please check that all author name spellings and affiliations are correct. 
 
Response: We have verified and corrected all author name spellings and affiliations (see 
lines 4-28). 
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6. For randomised trials please follow the CONSORT reporting guidelines 
(http://www.consort-statement.org) and CONSORT for abstracts 
(http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)61835-2/fulltext), and 
include a CONSORT checklist with your resubmission. 
 
Response: Not applicable because our study is not an RCT. 
 
7. Please ensure that the title of the paper is non-declamatory (ie, it describes the aim of study 
rather than the findings) and that it includes a description of the study type (eg, a randomised 
controlled trial). 
 
Response: The manuscript title is non-declamatory and includes a description of the 
study type. 
 
8. Please limit the summary to pre-defined primary endpoints and safety endpoints. 
 
Response: The summary is limited to the pre-defined primary endpoint. Safety 
endpoints are not applicable to this retrospective cohort study. 
 
9. For RCTs, please state the trial registration number. 
 
Response: Our study is not an RCT, but two of the cohorts which we analysed 
retrospectively are from RCTs. Their trial registration numbers are specified in lines 
165-166 and 184. 
 
10. At the end of the methods section please state the role of the funder in: data collection, 
analysis, interpretation, writing of the manuscript and the decision to submit.  Please also state 
which author(s) had access to all the data, and which author(s) were responsible for the 
decision to submit the manuscript etc. 
 
Response: The role of the funder is stated at the end of the methods section (see lines 
276-279). 
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11. Please explain any deviations from the protocol. 
 
Response: There was no deviation from the protocol. 
 
12. Please report all outcomes specified in the protocol. 
 
Response: All outcomes specified in the protocol are reported in the manuscript. 
 
13. If any exploratory outcomes are reported that were not pre-specified, please make it clear 
that these analyses were post-hoc. 
 
Response: All reported outcomes were pre-specified in the study protocol, and all 
exploratory analyses are described as post-hoc analyses in the manuscript. 
 
14. Please use rINNs for drug names. For genes and proteins, authors can use their preferred 
terminology so long as it is in current use by the community, but should provide the preferred 
human name from Uniprot (http://www.uniprot.org/uniprot/)  for proteins and HUGO 
(http://www.genenames.org) for genes at first use to assist non-specialists. 
 
Response: Not applicable for our manuscript. 
 
15. For drug studies, please ensure that details of doses, route of delivery, and schedule are 
included. 
 
Response: Not applicable for our study. 
 
16. For the main outcome measures, please include a result for each group, plus a point 
estimate (eg, RR, HR) with a measure of precision (eg, 95% CI) for the absolute difference 
between groups, in both the Summary and the main Results section of the paper. 
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Response: We have included hazard ratios with 95% confidence intervals in both the 




17. p-values should be exact, but no longer than 4 decimal places (eg p<0.0001). Two 
decimals are acceptable in tables for non-significant p-values 
 
Response: Exact p-values are provided with two significant digits, but no longer than 4 
decimal places. 
 
18. Please provide absolute numbers to accompany all percentages. Percentages should be 
rounded to whole numbers unless the study population is very large (>10 000 individuals). 
 
Response: Percentages are rounded to whole numbers and reported with the absolute 
numbers they were computed from. 
 
19. Please give 95% confidence intervals for hazard ratios/odds ratios. 
 
Response: 95% confidence intervals for hazard ratios have been provided. 
 
20. For means, please provide standard deviation (or error, as appropriate). 
 
Response: Not applicable because we have not reported any means. 
 
21. Please provide interquartile ranges for medians. 
 
Response: Interquartile ranges have been provided for medians (see line 330, and tables 
1 and 3). 
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22. Please provide numbers at risk for Kaplan-Meier plots and ensure that plots include a 
measure of effect (eg, log-rank p); estimates should be reported with 95% CIs. 
 
Response: Numbers at risk, log-rank p, and hazard ratios with 95% confidence intervals 
have been provided for Kaplan-Meier plots. 
 
23. Please ensure that the Discussion contains a section on limitations of the study. 
 
Response: The Discussion contains a section on limitations of the study in lines 411-420. 
 
24. Please provide the text, tables, and figures in an editable format. See link above this list 
for details of acceptable formats for figure files. 
 
Response: The text and tables are in Word format, and the figures are in the editable .ai 
format. 
 
25. Our production system is not compatible with Endnotes. Please convert to normal text. 
 
Response: The manuscript was converted to normal text without Endnote field codes 
before it was submitted. 
 
26. If accepted, only 5-6 non-text items (figures, tables, or panels) can be accommodated in 
the print edition; additional material can be provided in a web appendix. Please indicate which 
items can go in a web appendix. 
 
Response: The manuscript contains 2 figures and 3 tables, which can be accommodated 
in the print edition. 
 
THELANCET-D-19-03766R1: Response to comments Page 7 of 13 
27. Please provide a research in context panel with 3 parts: Evidence before this study (which 
includes a description of how you searched for evidence and how you assessed the quality of 
that evidence); Added value of the study; and Implications of all the available evidence. 
 
Response: Text for a research in context panel is provided in lines 73-108. 
 
28. At the end of the manuscript, please summarise the contribution of each author to the 
work. 
 
Response: The contribution of each author has been summarised at the end of the 
manuscript (see lines 428-436). 
 
29. At the end of the manuscript please summarise the declaration of interests for each author. 
 
Response: The declaration of interests for each author has been summarised at the end 
of the manuscript (see lines 438-443). 
 
30. If you have not yet done so, please return all signed authorship statements and conflict of 
interest forms. We also require signed statements from any named person in the 
acknowledgements saying that they agree to be acknowledged. 
 
Response: The signed authorship statements and conflict of interest forms for all except 
Prof. Rachel Kerr were uploaded with the first revision of the manuscript draft. The 
signed authorship statement and conflict of interest form from Prof. Rachel Kerr was 
emailed directly to the handling editor on 23
rd
 of October and to editorial@lancet.com 
on 24
th
 of October, and is also uploaded with the second revision of the manuscript 
draft. Consent forms from the two acknowledged persons were uploaded with the first 
revision of the manuscript draft. 
 
31. For any personal communication, please provide a letter showing that the person agrees to 
their name being used. 
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Response: Not applicable for our manuscript. 
 
32. As corresponding author, please confirm that all authors have seen and approved of the 
final text. 
 
Response: As the corresponding author, I confirm that all authors have seen and 
approved the final text. 
 
33. If your author line includes a study group, collaborators' names and affiliations may be 
listed at the end of the paper or in the appendix. Additionally, if you wish the names of 
collaborators within a study group to appear on PubMed, please upload with your revision a 
list of names of all study group members presented as a two-column table in Word. First and 
middle names or initials should be placed in the first column, and surnames in the second 
column. Names should be ordered as you wish them to appear on PubMed. The table will not 
be included in the paper itself - it's simply used to make sure that PubMed adds the names 
correctly. 
 
Response: Not applicable for our manuscript. 
 
34. Please note our guideline length for research articles is 3500 words and 30 references. For 
RCTs, the text can be expanded to 4500 words. 
 
Response: We have attempted to present the findings concisely and precisely, also when 
revising the manuscript according to the reviewers’ comments. The second revision of 
the manuscript draft contains 3889 words and 30 references. 
 
35. From July 1, 2018, all submitted reports of clinical trials must contain a data sharing 
statement, to be included at the end of the manuscript or in an appendix (please provide as a 
separate pdf). Data sharing statements must indicate: 
*Whether data collected for the study, including individual participant data and a data 
dictionary defining each field in the set, will be made available to others; 
*What data will be made available (deidentified participant data, participant data with 
identifiers, data dictionary, or other specified data set); 
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*Whether additional, related documents will be available (eg, study protocol, statistical 
analysis plan, informed consent form); 
*When these data will be available (beginning and end date, or "with publication", as 
applicable); 
*Where the data will be made available (including complete URLs or email addresses if 
relevant); 
*By what access criteria data will be shared (including with whom, for what types of 
analyses, by what mechanism - eg, with or without investigator support, after approval of a 
proposal, with a signed data access agreement - or any additional restrictions). 
 
Clinical trials that begin enrolling participants on or after Jan 1, 2019, must include a data 
sharing plan in the trial's registration. If the data sharing plan changes after registration, this 
should be reflected in the statement submitted and published, and updated in the registry 
record. For reports of research other than clinical trials, data sharing statements are 
encouraged but not required. Mendeley Data (https://data.mendeley.com) is a secure online 
repository for research data, permitting archiving of any file type and assigning a permanent 
and unique digital object identifier (DOI) so that the files can be easily referenced. If authors 
wish to share their supporting data, and have not already made alternative arrangements, a 
Mendeley DOI can be referred to in the data sharing statement. 
 
Response: Not applicable for our manuscript. 
 
 
Reviewer #1: Dear Editors and Authors, 
 
Thank you for the opportunity to review this revised article. I have re-read the article and 
author comments to reviewers. The authors have made an intelligent attempt to address 
reviewer concerns. 
 




THELANCET-D-19-03766R1: Response to comments Page 10 of 13 
1) It is recommended the authors define 'deep learning' in lay terms and perhaps contrast this 
with traditional machine learning in a few words for readers in the introduction section. 
 
Response: Thank you for helping us improve the presentation. We have revised lines 
138-147 to introduce deep learning in layman’s terms, separating it from traditional 
machine learning. 
 
2) The authors state "At the other end, stage III patients with DoMore-v1-CRC good 
prognosis, the great majority of whom are pN1, have very excellent survival with single -
agent c 440 apecitabine (figure 2E),". In the previous draft this was stated as 'very good' - now 
changed to 'excellent'. If the data has changed from the previous draft, then perhaps this 
should be highlighted here. If not then perhaps the language should be toned down a bit and 
reflect what was presented in the original draft. 
 
Response: The data has not changed. Line 400 has been revised according to your 
suggestion, i.e. the language has been toned down by using the original statement “very 
good” instead of “excellent”. 
 
3) I could not find the figures in this draft and therefore could not review them. Please ensure 
these are submitted to the editors. 
 
Response: We provided the figures in the editable format .ai since an editable format 
was requested in the 24
th
 editorial point. Since the submission system did not allow us to 
upload .ai files, the figure files were instead emailed directly to the handling editor. The 
content of the figures is identical in the original submission and in both revisions. 
 
 
Reviewer #2: The authors addressed most of the reviewers' concerns. Still, there are a few 




THELANCET-D-19-03766R1: Response to comments Page 11 of 13 
As requested, the authors added more extensive results for the Inception-V3 approach which 
is used for comparison. However, the approach is hardly mentioned in the manuscript itself as 
most of the results are in the appendix. The Inception-V3 model should be briefly introduced 
in the methods part and a few comments could be added in the discussion. In particular, the 
authors could briefly discuss the advantage of using the DoMore approach over the Inception-
V3 approach for clinical practice. This might not be obvious to the reader as the performance 
of the two approaches is close and, potentially, both could serve as a useful marker. Of 
course, the key contribution of this paper is to demonstrate that a deep learning-based marker 
could be useful for prognosis. For this contribution, the DoMore approach does not 
necessarily have to be better than other options (e.g. Inception-V3) for clinical use. In any 
case, this should be cleared up in the discussion. 
 
Response: In accordance to your suggestions, we have added lines 245-251 to introduce 
briefly the Inception v3 marker and lines 363-368 to discuss briefly the conceptual and 
practical differences between the two markers, noting in particular that both markers 
performed well, but that the DoMore-v1-CRC marker appears better and was the 






Protocol, p.15-16, description of Inception V3 training: The authors do not appear to use the 
data augmentation techniques as used for the DoMore architecture. In particular, there appears 
to be no random cropping and flipping/rotation. This would make the comparison not very 
meaningful as Inception-V3 might perform better with the same data augmentation scheme. 
This should be clarified. 
Response: While the study setup was identical for the two classification setups, the 
preprocessing and hyperparameters were adapted to the specific network (DoMore v1 
or Inception v3) in the discovery phase. This would ideally provide a fairer comparison 
between the potential of each network because the preprocessing and hyperparameters 
are then not adapted to one of the networks and possibly inappropriate for the other. 
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Reviewer comment:  From my understanding, the authors indicate that using the additional 
data augmentation used for DoMore (namely random cropping and flipping/rotation) does not 
increase performance for Inception-V3. Since these are standard augmentation techniques I 
am very surprised that they are not helpful for Inception-V3. The authors should state that 
they performed individual hyperparameter tuning for each approach (DoMore and Inception-
V3) beforehand which resulted in the selection of the different data augmentation techniques. 
 
Response: Thank you for helping us improve our presentation. We now specify in the 
revised lines 245-246 and 249-251 that while the study setup was identical for the two 
approaches (DoMore v1 and Inception v3), the image distortion algorithm and 
hyperparameters were independently determined in the discovery phase. The impact of 
applying random cropping and flipping/rotation in training may be much less in our 
study setup than in many other setups because of our vast amount of training images 
(i.e. the number of tiles used for training); even when trained beyond apparent 
convergence, the training of Inception v3 only ran for 3.78 epochs for the 10x networks 
and 0.41 epochs for the 40x networks. Combined with the applied colour distortion, 
which was arguably more comprehensive for the Inception v3 training than for the 
DoMore v1 training (see protocol pp 14-15), it should be highly unlikely that the 
networks learn to associate many features unique to the training images with the patient 
outcome. The markers’ consistently strong performances in the independent cohorts 




* The code and dataset (or at least the code + model weights) should be posted online for 
replication of the study and to facilitate future research in this domain. 
Response: Our goal is to improve the management of many cancer patients. Since 
commercialisation may be necessary to facilitate widespread adaption in routine medical 
practice, the Research Council of Norway encouraged projects in the IKTPLUSS 
Lighthouse program to commercialise products supported by the grant. We currently 
evaluate such possibilities, and are therefore at present not able to provide code and 
model weights to the public community. We have however endeavoured to describe all 
methods with full details, which should enable other researchers to apply the same 
principles in their own studies. 
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Reviewer comment: It is understandable that further commercialization could happen. 
However, this prevents the reproduction of the paper's results. Can the authors comment on 
the option of making the data publicly available in some way? In my point of view, this would 
benefit the scientific community much more than a code/model weights release. 
 
Response: Thank you for your understanding. We agree that well-curated datasets 
could benefit the scientific community and will attempt to solve any ethical, legal and 
practical issues concerning publicising the raw data that were analysed in this study. 
This involves a series of institutions in multiple countries, and the raw data cannot be 
made publically available until all parties have agreed and verified that such 
distribution does not violate any obligations they may have to the patients, institutions 
or governments. 
Table 1: Patient characteristics in the training, tuning, test and validation cohorts 
 
Group Training cohort Tuning cohort Test cohort Validation cohort 
 
 (N=828) (N=1645) (N=920) (N=1122) 
Age, years  69 (61-75) 70 (61-77) 71 (64-78) 65 (59-71) 
Sex  
   
  
 Female 402 (51%) 689 (42%) 421 (46%) 477 (43%) 
 Male 426 (49%) 956 (58%) 499 (54%) 645 (57%) 
Stage  
   
  
 I 101 (12%) 102 (6%) 70 (8%)   
 II 317 (38%) 797 (48%) 354 (38%) 402 (36%) 
 III 410 (50%) 746 (45%) 496 (54%) 720 (64%) 
pN stage  
   
  
 pN0 415 (50%) 891 (54%) 425 (46%) 402 (36%) 
 pN1 241 (29%) 492 (30%) 258 (28%) 508 (45%) 
 pN2 167 (20%) 239 (15%) 237 (26%) 183 (16%) 
 Missing 5 (1%) 23 (1%) 0 (0%) 29 (3%) 
pT stage  
   
  
 pT1 26 (3%) 30 (2%) 6 (1%) 17 (2%) 
 pT2 110 (13%) 137 (8%) 65 (7%) 71 (6%) 
 pT3 464 (56%) 1034 (63%) 411 (45%) 582 (52%) 
 pT4 223 (27%) 423 (26%) 437 (48%) 404 (36%) 
 Missing 5 (1%) 21 (1%) 1 (0%) 48 (4%) 
Histological grade  
   
  
 1 77 (9%) 196 (12%) 134 (15%) 45 (4%) 
 2 568 (69%) 1151 (70%) 489 (53%) 846 (75%) 
 3 178 (21%) 280 (17%) 297 (32%) 168 (15%) 
 Missing 5 (1%) 18 (1%) 0 (0%) 63 (6%) 
Location  
   
  
 Rectum 222 (27%) 457 (28%) 311 (34%) 165 (15%) 
 Distal colon 262 (32%) 533 (32%) 280 (30%) 451 (40%) 
 Proximal colon 307 (37%) 505 (31%) 329 (36%) 453 (40%) 
 Missing 37 (4%) 150 (9%) 0 (0%) 53 (5%) 
Adjuvant treatment  
   
  
 No 467 (56%) 826 (50%) 538 (58%) 0 (0%) 
 Chemotherapy 173 (21%) 397 (24%) 51 (6%) 1122 (100%) 
 Radiotherapy 11 (1%) 6 (0%) 14 (2%) 0 (0%) 
 
Chemo- and 
radiotherapy 3 (0%) 9 (1%) 3 (0%) 0 (0%) 
 Missing 174 (21%) 407 (25%) 314 (34%) 0 (0%) 
Follow-up time, years  6·4 (1·7-8·2) 4·0 (2·2-5·2) 2·4 (1·0-4·6) 4·6 (3·3-5·1) 
 




Table 2: Multivariable cancer-specific survival analyses in the validation cohort; the multivariable model included the DoMore-v1-CRC 
class evaluated on Aperio AT2 slide images, and established prognostic markers that were significant in the corresponding stage-specific 
univariable analyses in the validation cohort 
 
Group Stage II and III Stage II Stage III 












ref.   




2·14 (1·15-3·99)   








   
<0·0001 
  pN0 ref. 
    
  
  pN1 1·84 (1·13-2·98) 
   
ref.   
  pN2 5·94 (3·71-9·52) 
   




   
0·014 
  pT1 NA 
   
NA   
  pT2 1·86 (0·90-3·86) 
   
1·68 (0·64-4·45)   
  pT3 ref. 
   
ref.   
  pT4 1·75 (1·22-2·51) 
   
2·07 (1·33-3·22)   
Lymphatic invasion Yes 1·66 (1·07-2·56) 0·023 
  
1·98 (1·20-3·28) 0·0079 
Venous vascular invasion Yes 1·07 (0·76-1·51) 0·71 
  
0·98 (0·64-1·52) 0·94 
Sidedness Right 
    





  1·39 (0·81-2·40) 0·24 
 
Ref.=reference; NA=not available 
Table 2











prognosis Spearman's correlation 
 
 (N=704) (N=136) (N=270) ρ (95% CI) p 
Age (continuous), years  64 (58-71) 65 (60-71) 66 (60-72) 0·07 (0·01 to 0·13) 0·024 
Age (dichotomous), years  
   
0·03 (-0·03 to 0·09) 0·38 
 ≤72 568 (81%) 112 (82%) 209 (77%) 
 
  




   
-0·02 (-0·08 to 0·04) 0·59 
 Female 297 (42%) 53 (39%) 122 (45%) 
 
  




   
0·04 (-0·02 to 0·10) 0·20 
 II 261 (37%) 48 (35%) 88 (33%) 
 
  
 III 443 (63%) 88 (65%) 182 (67%) 
 
  
Stage with substage  
   
0·15 (0·09 to 0·21) <0·0001 
 IIA 143 (21%) 19 (14%) 28 (11%) 
 
  
 IIB 110 (16%) 27 (20%) 54 (21%) 
 
  
 IIIA 67 (10%) 2 (2%) 6 (2%) 
 
  
 IIIB 269 (40%) 51 (38%) 104 (41%) 
 
  
 IIIC 83 (12%) 34 (26%) 64 (25%) 
 
  
pN stage  
   
0·10 (0·04 to 0·16) 0·0008 
 pN0 261 (38%) 48 (36%) 88 (33%) 
 
  
 pN1 339 (50%) 53 (39%) 111 (42%) 
 
  
 pN2 83 (12%) 34 (25%) 64 (24%) 
 
  
pT stage  
   
0·26 (0·21 to 0·32) <0·0001 
 pT1 15 (2%) 0 (0%) 2 (1%) 
 
  
 pT2 61 (9%) 3 (2%) 6 (2%) 
 
  
 pT3 402 (60%) 75 (56%) 100 (39%) 
 
  
 pT4 194 (29%) 56 (42%) 148 (58%) 
 
  
Lymphatic invasion  
   
0·04 (-0·02 to 0·10) 0·20 
 No 599 (91%) 122 (92%) 220 (87%) 
 
  
 Yes 62 (9%) 10 (8%) 33 (13%) 
 
  
Venous vascular invasion  
   
0·05 (-0·01 to 0·11) 0·11 
 No 409 (61%) 74 (56%) 145 (56%) 
 
  
 Yes 257 (39%) 58 (44%) 112 (44%) 
 
  
Histological grade  
   
0·14 (0·08 to 0·20) <0·0001 
 1 27 (4%) 7 (6%) 8 (3%) 
 
  
 2 565 (85%) 88 (69%) 186 (74%) 
 
  




   
0·15 (0·09 to 0·21) <0·0001 
 













   
0·14 (0·08 to 0·20) <0·0001 
 Left 419 (63%) 67 (51%) 123 (47%) 
 
  




   
-0·06 (-0·12 to 0·00) 0·069 
 Wild-type 410 (65%) 86 (73%) 169 (70%) 
 
  




   
0·22 (0·16 to 0·28) <0·0001 




 Mutated 47 (7%) 29 (25%) 56 (23%) 
 
  
Microsatellite instability  
   
-0·10 (-0·16 to -0·04) 0·0018 
 Yes 66 (10%) 26 (21%) 40 (16%) 
 
  
 No 595 (90%) 99 (79%) 213 (84%) 
 
  
Follow-up time, years  4·8 (3·7-5·1) 4·9 (3·1-5·1) 4·1 (2·8-5·1) -0·10 (-0·16 to -0·04) 0·0006 
 
Data are median (IQR) or number (%). IQR=interquartile range. 
  
Appendix with protocol
Click here to download Supplementary Material: appendix_with_protocol.pdf
  
Video
Click here to download Video: THELANCET-D-19-03766.mp4
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Search criteria used in “Evidence before this study” 
In the “Research in context” panel, the PubMed search outlined under “Evidence before this study” was the user 
query: 
("deep learning" OR "machine learning") AND (prediction OR prognosis OR classification) AND (survival OR 
outcome) AND (cancer OR tumor OR tumour) AND (histology OR histopathology) 
PubMed translated this user query into the following detailed search query: 
("deep learning"[All Fields] OR "machine learning"[All Fields]) AND (prediction[All Fields] OR 
("prognosis"[MeSH Terms] OR "prognosis"[All Fields]) OR ("classification"[Subheading] OR 
"classification"[All Fields] OR "classification"[MeSH Terms])) AND (("mortality"[Subheading] OR 
"mortality"[All Fields] OR "survival"[All Fields] OR "survival"[MeSH Terms]) OR outcome[All Fields]) AND 
(("neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All Fields]) OR ("tumour"[All Fields] 
OR "neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "tumor"[All Fields]) OR ("tumour"[All Fields] 
OR "neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "tumor"[All Fields])) AND (("anatomy and 
histology"[Subheading] OR ("anatomy"[All Fields] AND "histology"[All Fields]) OR "anatomy and 
histology"[All Fields] OR "histology"[All Fields] OR "histology"[MeSH Terms]) OR ("pathology"[Subheading] 






What follows is a description of a general framework for classifying images using multiple instance learning. 
The DoMore v1 network presented in the main text is a particular version of this general network architecture. 
Similar architectures in the context of image classification with multiple instance learning are described in the 




The purpose of the method is to classify an image, and involves partitioning the original image into a number of 
smaller patches, called tiles. The collection of all tiles in an image is denoted 𝐼. A collection of tiles from the 
same image is called a bag, and a collection of bags is called a batch (or mini-batch). None of the individual tiles 
are assigned a label, instead the bag of tiles inherits the label of the image from where it originates. We will 
denote a bag as a collection of tiles, 𝐵 ⊆ 𝐼. 
 
An integral part of this multiple instance learning method is an artificial neural network consisting of main parts: 
a representation network, a pooling function, and a classification network, all of which can be selected 
independently to fit a particular task. One update step of the training is listed below 
 
1. A batch of bags are input to the network 
2. The representation network maps each tile to a representation of the tile 
3. Representations are aggregated by the pooling function 
4. A classification network takes pooled representations as input and produce a prediction 
5. This prediction is compared with a reference classification using some loss function 
6. Derivatives of the loss function with respect to the parameters of the network is used to update the 
respective parameters 
 
The representation network, the pooling function, and the final classification network, all can have trainable 
parameters, and the entire network is trained end-to-end. 
 
In the rest of the description, we will ignore the batch dimension (and implicitly assume a batch size of one). 




The representation network is a function 𝑓𝑟: ℝ
m×n×c → ℝs that maps a tile 𝑥 with shape 
𝑚 × 𝑛 × 𝑐 to some feature representation of the tile 𝑓𝑟(𝑥; 𝜃𝑟) with size 𝑠. This function can for example be a 
regular convolutional neural network. The trainable parameters associated with the representation network are 
denoted 𝜃𝑟. 
 
The representation network is applied on all tiles in a bag 𝐵, producing a bag of representations 𝑅 =
{𝑓𝑟(𝑥; 𝜃𝑟): 𝑥 ∈  𝐵}. Note that within the same update, all tiles in a bag, and all bags in a batch uses the exact 
same representation network with the same values of 𝜃𝑟. All representations within a batch have to be computed, 
and stored, before the next step. 
 
Pooling function 
The pooling function reduce the set of tile representations 𝑅 to a single representation for one bag 𝐵, and is 
typically a function 𝑓𝑝: ℝ
b×s → ℝt, where 𝑏 is the number of tiles in a bag. Since this function potentially is 
dependent on the final representations of all tiles in a bag, it cannot be computed before all those representations 
are computed. This function can also have trainable parameters, the collection of which is denoted 𝜃𝑝. 
 
Classification network 
The final part of the network is a classification network 𝑓𝑐: ℝ
t → ℝk, where 𝑘 is the number of classes. This 
function is parameterised with its own set of trainable parameters 𝜃𝑐, the output range is typically [0, 1] and such 
that ∑ 𝑓𝑐(𝑥; 𝜃𝑐)𝑖
𝑘
𝑖=1 = 1 for all fitting inputs 𝑥 ∈ ℝ
t . With this, the output of this function can be interpreted as 
a prediction probability over the possible output classes, conditioned on the input. Note that all tiles in a bag 







The full network 𝑓: ℝb×m×n×c → ℝk produce a prediction 𝑓(𝐵;  𝜃𝑟 , 𝜃𝑝, 𝜃𝑐) for each bag of tiles 𝐵, and this 
prediction is compared with a reference label assigned to the bag using a loss function 𝐿. In the following we 




Ideally, one would like the tiles in a bag to span the entire image, but hardware constraints often necessitates 
subsampling. In principle, one can sample tiles from an image in many different ways, but assuming no prior 
knowledge, a uniform random sampling without replacement is sufficient. With a random subsampling of tiles, it 
is unlikely that an image will be represented by the same configuration of tiles each time. This could have a 
regularising effect on the training, and help generalisation. 
 
A bag is given the label of its origin image, and if the tiles in a bag does not span the entire image, this 
assignment is not entirely justified. The assumption is, however, that the error made in assigning the image label 
to a bag of tiles is smaller than assigning the image label to a single tile. Implicit in this assumption is that the 
approximation error decreases with an increasing area represented by the tiles in a bag, ranging from a bag with 
one single tile to a bag containing all tiles in an image. 
 
Truncated gradient contribution 
It is desirable to use as many tiles as possible to represent an image in an update step of the optimisation, and for 
large images, the number of tiles per bag is limited by the memory of the hardware the method runs on. The 
representation network is the largest consumer of memory in this framework. In the forward propagation, all tiles 
in a bag are processed by the representation network, but only a representation of the tiles, with a considerable 
smaller size, is used further in the forward propagation. A gradient-based optimisation method makes use of 
intermediate representations of each tile “within” the network to update the parameters of the network. This 
means that these intermediate representations are stored until the relevant gradients are computed. By reducing 
the number of tiles used in the backpropagation, we would significantly reduce the memory footprint. The 
proposed method is to use the entire bag 𝐵 in the forward propagation of the representation network, but only a 
subset 𝐺 ⊆ 𝐵 of the bag in the backward propagation. Note that it is only the representation network that employ 
this truncation of gradient contributions. All tile representations from a bag are used by the pooling function and 
therefore by the final classification network, and the update of parameters associated with the pooling function 
and the classification network is not affected with the truncation in the representation network. It is hypothesised 
that increasing the size of G with B fixed will aid the optimisation. It is also hypothesised that increasing the size 
of B with G fixed will aid the optimisation. 
 
Inference 
In order to classify an image with a trained network, the image is tiled, and the representation network is applied 
on all tiles in the image. This can be done on one tile at the time, and each tile representation is stored until all 
tiles are processed by the representation network. Each tile representation is very small, so the number of tiles 
per image in inference is for all practical purposes almost limitless with respect to memory. The tile 
representations are aggregated by the pooling function, and the classification network produces a classification 
for the entire image. 
 
Even though the bag size often is different in training and inference, a successfully trained network seems to 
produce reasonable results. Since the network uses all tiles in an image for inference, an image is usually better 
represented in inference than in training. The difficulty is often to make the network learn features that can be 
generalised over the entire image, which is one of the reasons why it is important with a large bag size. 
 
Example 
In the method presented in the main manuscript, the following values are used. The representation network 𝑓𝑟 is 
MobileNet v2,3 and the pooling function 𝑓𝑝 is NoisyAND.
1 The classification network 𝑓𝑐 is an ordinary fully 
connected neural network. The tile representation size, s is 2, and the number of inputs to the final classification 
network, t is also 2. Finally, the number of classes, k, is 2. In training the network, we use a batch size of 32, a 
bag size |B| of 64 and the number of tiles contributing to the gradient approximation |G| is 8, with an input tile 





DoMore-v1-CRC classifier with five risk groups 
In a post-hoc analysis, the continuous DoMore-v1-CRC score was categorised into five risk groups. This 
classifier was designed by computing the c-index of the categorised DoMore-v1-CRC score in the tuning cohort 
for all possible combination of four thresholds with values 0·01, 0·02, and so on up to 0·99, filtering in the c-
index space by a 61 elements wide Gaussian kernel with standard deviation 0·1, and selecting the threshold 
combination that maximised the filtered c-index. The selected thresholds defined five risk groups by categorising 
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Table S1: REporting recommendations for tumour MARKer prognostic studies (REMARK) checklist 
 
Item to be reported Where reported Comments 
INTRODUCTION   
1 State the marker examined, the study objectives, and any pre-specified hypotheses.   Introduction, Methods, 
appendix 
 
MATERIALS AND METHODS   
Patients   
2 Describe the characteristics (e.g., disease stage or co-morbidities) of the study 
patients, including their source and inclusion and exclusion criteria.   
Methods  
3 Describe treatments received and how chosen (e.g., randomized or rule-based).   Methods  
Specimen characteristics   
4 Describe type of biological material used (including control samples) and methods of 
preservation and storage. 
Methods, appendix  
Assay methods   
5 Specify the assay method used and provide (or reference) a detailed protocol, 
including specific reagents or kits used, quality control procedures, reproducibility 
assessments, quantitation methods, and scoring and reporting protocols. Specify 
whether and how assays were performed blinded to the study endpoint. 
Methods Standard H&E stained sections. 
Study design   
6 State the method of case selection, including whether prospective or retrospective 
and whether stratification or matching (e.g., by stage of disease or age) was used. 
Specify the time period from which cases were taken, the end of the follow-up 
period, and the median follow-up time.   
Methods  
7 Precisely define all clinical endpoints examined.  Methods  
8 List all candidate variables initially examined or considered for inclusion in models.  Protocol  
9 Give rationale for sample size; if the study was designed to detect a specified effect 
size, give the target power and effect size.  
 Included as many samples as possible to 
represent variation. 
Statistical analysis methods   
10 Specify all statistical methods, including details of any variable selection procedures 
and other model-building issues, how model assumptions were verified, and how 
missing data were handled.  
Methods, protocol  
11 Clarify how marker values were handled in the analyses; if relevant, describe 
methods used for cutpoint determination. 
Protocol  
RESULTS   
Data    
12 Describe the flow of patients through the study, including the number of patients 
included in each stage of the analysis (a diagram may be helpful) and reasons for 
dropout. Specifically, both overall and for each subgroup extensively examined 
report the numbers of patients and the number of events. 
Protocol  
13 Report distributions of basic demographic characteristics (at least age and sex), 
standard (disease-specific) prognostic variables, and tumor marker, including 
numbers of missing values.  
Table 1  
Analysis and presentation    
14 Show the relation of the marker to standard prognostic variables. Tables 2 and 3  
15 Present univariable analyses showing the relation between the marker and outcome, 
with the estimated effect (e.g., hazard ratio and survival probability). Preferably 
provide similar analyses for all other variables being analyzed. For the effect of a 
tumor marker on a time-to-event outcome, a Kaplan-Meier plot is recommended.  
Results, table 2, figure 
2, appendix 
 
16 For key multivariable analyses, report estimated effects (e.g., hazard ratio) with 
confidence intervals for the marker and, at least for the final model, all other 
variables in the model.  
Table 2  
17 Among reported results, provide estimated effects with confidence intervals from an 
analysis in which the marker and standard prognostic variables are included, 
regardless of their statistical significance.  
Table 2 Included variables that were significant 
in univariable analysis of cancer-
specific survival. 
18 If done, report results of further investigations, such as checking assumptions, 
sensitivity analyses, and internal validation. 
Ok  Internally tested in new tumour blocks 
prepared at a different pathology 
laboratory, then independently validated 
in a clinical trial cohort (QUASAR 2). 
DISCUSSION   
19 Interpret the results in the context of the pre-specified hypotheses and other relevant 
studies; include a discussion of limitations of the study. 
Discussion  




Table S2: Checklist for developing and reporting machine learning predictive models in 
biomedical research proposed by Luo et al 
Item number Topic Checklist item 
1 Nature of the study Ok, main manuscript (Title). 
2 Structured summary Ok, main manuscript (Abstract). 
3 Rationale Ok, main manuscript (Introduction). 
4 Objectives Ok, main manuscript (Introduction), although predictive 
modelling commonly refers to prediction based on multiple 
relevant variables, whereas our study reports on the 
development and independent validation of a single marker 
which we propose to use in combination with established 
clinicopathological parameters. 
5 Describe the setting Ok, main manuscript (“Evidence before this study” and 
Introduction) and protocol. 
6 Define the prediction problem Ok, main manuscript (Introduction and Methods) and protocol. 
Development and independent validation of a prognostic marker 
in retrospective datasets. Not all fields are applicable to our 
study. 
7 Prepare data for model building Ok, protocol. 
8 Build the predictive model Ok, main manuscript (Methods) and protocol. Not all fields are 
applicable to our study. 
9 Report the final model and 
performance 
Ok, main manuscript (tables 2 and 3) and appendix. 
10 Clinical implications Ok, main manuscript (“Added value of this study” and 
Discussion). 
11 Limitations of the model Ok, main manuscript (Discussion). 






Table S3: Univariable cancer-specific survival analyses in the validation cohort of the DoMore-v1-CRC class and score, its 
constituents, and established prognostic markers 
 
Variable Group  Stage II and III  Stage II  Stage III 
      HR (95% CI) p   HR (95% CI) p   HR (95% CI) p 
DoMore-v1-CRC class on Aperio AT2    <0·0001   0·028   <0·0001 
  Good prognosis  ref.   ref.   ref.   
  Uncertain  1·89 (1·14-3·15)   1·22 (0·35-4·24)   2·07 (1·18-3·63)   
  Poor prognosis  3·84 (2·72-5·43)   2·71 (1·25-5·86)   4·09 (2·77-6·03)   
10x ensemble class on Aperio AT2 Poor prognosis  3·26 (2·37-4·49) <0·0001  2·42 (1·16-5·08) 0·015  3·40 (2·38-4·85) <0·0001 
40x ensemble class on Aperio AT2 Poor prognosis  3·19 (2·30-4·42) <0·0001  2·32 (1·12-4·80) 0·020  3·38 (2·34-4·88) <0·0001 
DoMore-v1-CRC score on Aperio AT2 25% increment  2·48 (1·98-3·11) <0·0001  2·02 (1·19-3·44) 0·0095  2·54 (1·97-3·27) <0·0001 
10x ensemble score on Aperio AT2 25% increment  2·16 (1·80-2·61) <0·0001  1·84 (1·18-2·85) 0·0070  2·20 (1·79-2·70) <0·0001 
40x ensemble score on Aperio AT2 25% increment  2·69 (2·05-3·53) <0·0001  2·09 (1·12-3·92) 0·021  2·80 (2·07-3·80) <0·0001 
DoMore-v1-CRC class on NanoZoomer XR    <0·0001   0·0021   <0·0001 
  Good prognosis  ref.   ref.   ref.   
  Uncertain  2·42 (1·45-4·03)   2·78 (0·84-9·25)   2·22 (1·26-3·91)   
  Poor prognosis  3·39 (2·36-4·87)   4·00 (1·74-9·20)   3·20 (2·14-4·80)   
10x ensemble class on NanoZoomer XR Poor prognosis  3·34 (2·38-4·68) <0·0001  3·89 (1·78-8·49) 0·0002  3·18 (2·19-4·63) <0·0001 
40x ensemble class on NanoZoomer XR Poor prognosis  2·46 (1·78-3·40) <0·0001  2·87 (1·37-6·04) 0·0035  2·31 (1·61-3·32) <0·0001 
DoMore-v1-CRC score on NanoZoomer XR 25% increment  2·51 (1·98-3·19) <0·0001  2·64 (1·54-4·50) 0·0004  2·44 (1·87-3·18) <0·0001 
10x ensemble score on NanoZoomer XR 25% increment  2·18 (1·80-2·65) <0·0001  2·26 (1·46-3·50) 0·0003  2·12 (1·71-2·64) <0·0001 
40x ensemble score on NanoZoomer XR 25% increment  2·73 (2·04-3·64) <0·0001  2·93 (1·52-5·67) 0·0014  2·65 (1·93-3·64) <0·0001 
pN stage    <0·0001      <0·0001 
  pN0  ref.         
  pN1  1·49 (0·95-2·32)      ref.   
  pN2  6·18 (4·00-9·54)      4·15 (2·89-5·96)   
pT stage    <0·0001   0·96   <0·0001 
  pT1  n/a      n/a   
  pT2  1·34 (0·66-2·71)      1·18 (0·58-2·42)   
  pT3  ref.   ref.   ref.   
  pT4  2·19 (1·56-3·07)   1·02 (0·49-2·14)   3·39 (2·31-4·98)   
Lymphatic invasion Yes  1·87 (1·22-2·89) 0·0037  0·34 (0·05-2·50) 0·27  2·33 (1·49-3·65) 0·0001 
Venous vascular invasion Yes  1·48 (1·07-2·05) 0·018  1·11 (0·52-2·37) 0·78  1·74 (1·21-2·50) 0·0023 
Age at randomisation 10-year increment  1·12 (0·95-1·33) 0·19  0·94 (0·65-1·37) 0·76  1·13 (0·93-1·36) 0·21 
Sex Male  1·12 (0·81-1·55) 0·49  1·38 (0·65-2·96) 0·40  1·09 (0·76-1·57) 0·63 
Histological grade    0·24   0·91   0·057 
  1  ref.   ref.   ref.   
  2  1·23 (0·50-3·02)   1·30 (0·18-9·68)   1·19 (0·44-3·24)   
  3  1·72 (0·66-4·45)   1·07 (0·12-9·55)   2·02 (0·70-5·82)   
Sidedness Right  1·24 (0·89-1·72) 0·20  0·78 (0·37-1·67) 0·52  1·60 (1·11-2·30) 0·010 
KRAS Mutated  1·09 (0·77-1·54) 0·64  1·17 (0·55-2·51) 0·68  1·03 (0·69-1·53) 0·89 
BRAF Mutated  1·54 (0·99-2·39) 0·054  1·24 (0·47-3·23) 0·67  1·71 (1·04-2·81) 0·033 




Table S4: Multivariable cancer-specific survival analyses in the validation cohort; the multivariable model included the 
10x ensemble class of the DoMore v1 network evaluated on Aperio AT2 slide images, and established prognostic markers 
that were significant in the corresponding stage-specific univariable analyses in the validation cohort 
 
Variable Group  Stage II and III  Stage II  Stage III 
      HR (95% CI) p   HR (95% CI) p   HR (95% CI) p 
10x ensemble class Poor prognosis  2·62 (1·85-3·71) <0·0001  2·42 (1·16-5·08) 0·015  2·40 (1·56-3·69) 0·0001 
pN stage    <0·0001      <0·0001 
  pN0  ref.         
  pN1  1·86 (1·15-3·02)      ref.   
  pN2  6·19 (3·88-9·89)      3·47 (2·25-5·35)   
pT stage    0·011      0·012 
  pT1  n/a      n/a   
  pT2  1·76 (0·86-3·64)      1·51 (0·58-3·95)   
  pT3  ref.      ref.   
  pT4  1·80 (1·26-2·59)      2·12 (1·36-3·29)   
Lymphatic invasion Yes  1·70 (1·10-2·63) 0·017     2·00 (1·21-3·31) 0·0069 
Venous vascular invasion Yes  1·08 (0·77-1·53) 0·66     1·02 (0·66-1·57) 0·92 
Sidedness Right        1·09 (0·70-1·69) 0·70 




Table S5: Multivariable cancer-specific survival analyses in the validation cohort; the multivariable model included the 
40x ensemble class of the DoMore v1 network evaluated on Aperio AT2 slide images, and established prognostic markers 
that were significant in the corresponding stage-specific univariable analyses in the validation cohort 
 
Variable Group  Stage II and III  Stage II  Stage III 
      HR (95% CI) p   HR (95% CI) p   HR (95% CI) p 
40x ensemble class Poor prognosis  2·51 (1·75-3·59) <0·0001  2·32 (1·12-4·80) 0·020  2·59 (1·64-4·08) <0·0001 
pN stage    <0·0001      <0·0001 
  pN0  ref.         
  pN1  1·88 (1·16-3·05)      ref.   
  pN2  5·82 (3·63-9·32)      3·22 (2·08-4·98)   
pT stage    0·0046      0·0068 
  pT1  n/a      n/a   
  pT2  1·85 (0·89-3·85)      1·66 (0·63-4·37)   
  pT3  ref.      ref.   
  pT4  1·88 (1·32-2·69)      2·17 (1·40-3·35)   
Lymphatic invasion Yes  1·63 (1·06-2·53) 0·027     1·96 (1·18-3·24) 0·0089 
Venous vascular invasion Yes  1·08 (0·76-1·52) 0·67     0·98 (0·64-1·51) 0·93 
Sidedness Right        1·12 (0·72-1·74) 0·61 




Table S6: Areas under the curve (AUC) for patients with distinct 
outcome and Harrell's concordance index for all patients in the 
validation cohort, both with 95% confidence intervals (CIs), 
between cancer-specific survival and a DoMore v1 individual 
model score 
 
Variable AUC (95% CI) c-index (95% CI) 
10x model 1 score on Aperio AT2 0·713 (0·624-0·790) 0·681 (0·632-0·724) 
10x model 2 score on Aperio AT2 0·702 (0·610-0·779) 0·671 (0·620-0·716) 
10x model 3 score on Aperio AT2 0·705 (0·614-0·782) 0·662 (0·612-0·708) 
10x model 4 score on Aperio AT2 0·680 (0·591-0·757) 0·656 (0·606-0·702) 
10x model 5 score on Aperio AT2 0·740 (0·651-0·815) 0·676 (0·626-0·720) 
40x model 1 score on Aperio AT2 0·681 (0·589-0·760) 0·660 (0·612-0·707) 
40x model 2 score on Aperio AT2 0·682 (0·592-0·762) 0·634 (0·585-0·680) 
40x model 3 score on Aperio AT2 0·686 (0·594-0·763) 0·648 (0·599-0·695) 
40x model 4 score on Aperio AT2 0·697 (0·605-0·776) 0·660 (0·611-0·707) 
40x model 5 score on Aperio AT2 0·711 (0·618-0·785) 0·671 (0·623-0·718) 
10x model 1 score on NanoZoomer XR 0·702 (0·612-0·779) 0·670 (0·621-0·714) 
10x model 2 score on NanoZoomer XR 0·707 (0·619-0·784) 0·670 (0·619-0·715) 
10x model 3 score on NanoZoomer XR 0·720 (0·635-0·795) 0·664 (0·614-0·707) 
10x model 4 score on NanoZoomer XR 0·712 (0·626-0·787) 0·667 (0·616-0·710) 
10x model 5 score on NanoZoomer XR 0·723 (0·633-0·800) 0·672 (0·621-0·718) 
40x model 1 score on NanoZoomer XR 0·700 (0·612-0·776) 0·650 (0·602-0·696) 
40x model 2 score on NanoZoomer XR 0·665 (0·575-0·746) 0·631 (0·584-0·677) 
40x model 3 score on NanoZoomer XR 0·696 (0·607-0·772) 0·647 (0·600-0·693) 
40x model 4 score on NanoZoomer XR 0·682 (0·590-0·759) 0·654 (0·604-0·699) 




Table S7: Multivariable cancer-specific survival analyses in the validation cohort; the multivariable model included the 
average of the two DoMore v1 ensemble scores evaluated on Aperio AT2 slide images, and established prognostic markers 
that were significant in the corresponding stage-specific univariable analyses in the validation cohort 
 
Variable Group  Stage II and III  Stage II  Stage III 
      HR (95% CI) p   HR (95% CI) p   HR (95% CI) p 
DoMore-v1-CRC score 25% increment  2·11 (1·63-2·73) <0·0001  2·02 (1·19-3·44) 0·0095  1·97 (1·42-2·73) <0·0001 
pN stage    <0·0001      <0·0001 
  pN0  ref.         
  pN1  1·78 (1·10-2·89)      ref.   
  pN2  5·87 (3·68-9·38)      3·46 (2·25-5·32)   
pT stage    0·012      0·017 
  pT1  n/a      n/a   
  pT2  2·04 (0·98-4·23)      1·74 (0·66-4·60)   
  pT3  ref.      ref.   
  pT4  1·74 (1·21-2·50)      2·03 (1·30-3·17)   
Lymphatic invasion Yes  1·70 (1·10-2·62) 0·018     2·06 (1·25-3·40) 0·0046 
Venous vascular invasion Yes  1·03 (0·73-1·46) 0·86     0·99 (0·64-1·52) 0·96 
Sidedness Right        1·09 (0·70-1·69) 0·71 




Table S8: Multivariable cancer-specific survival analyses in the validation cohort; the multivariable model included the 
10x ensemble score of the DoMore v1 network evaluated on Aperio AT2 slide images, and established prognostic markers 
that were significant in the corresponding stage-specific univariable analyses in the validation cohort 
 
Variable Group  Stage II and III  Stage II  Stage III 
      HR (95% CI) p   HR (95% CI) p   HR (95% CI) p 
10x ensemble score 25% increment  1·90 (1·54-2·35) <0·0001  1·84 (1·18-2·85) 0·0070  1·79 (1·37-2·34) <0·0001 
pN stage    <0·0001      <0·0001 
  pN0  ref.         
  pN1  1·76 (1·08-2·85)      ref.   
  pN2  5·94 (3·72-9·48)      3·53 (2·29-5·44)   
pT stage    0·017      0·020 
  pT1  n/a      n/a   
  pT2  2·03 (0·98-4·21)      1·75 (0·66-4·62)   
  pT3  ref.      ref.   
  pT4  1·71 (1·19-2·45)      2·01 (1·29-3·14)   
Lymphatic invasion Yes  1·70 (1·10-2·63) 0·017     2·07 (1·26-3·41) 0·0043 
Venous vascular invasion Yes  1·03 (0·73-1·46) 0·85     0·99 (0·65-1·53) 0·98 
Sidedness Right        1·09 (0·70-1·70) 0·69 




Table S9: Multivariable cancer-specific survival analyses in the validation cohort; the multivariable model included the 
40x ensemble score of the DoMore v1 network evaluated on Aperio AT2 slide images, and established prognostic markers 
that were significant in the corresponding stage-specific univariable analyses in the validation cohort 
 
Variable Group  Stage II and III  Stage II  Stage III 
      HR (95% CI) p   HR (95% CI) p   HR (95% CI) p 
40x ensemble score 25% increment  2·20 (1·62-2·99) <0·0001  2·09 (1·12-3·92) 0·021  2·08 (1·41-3·07) 0·0002 
pN stage    <0·0001      <0·0001 
  pN0  ref.         
  pN1  1·84 (1·14-2·99)      ref.   
  pN2  5·89 (3·69-9·42)      3·35 (2·18-5·16)   
pT stage    0·0019      0·0094 
  pT1  n/a      n/a   
  pT2  1·95 (0·94-4·05)      1·68 (0·64-4·45)   
  pT3  ref.      ref.   
  pT4  1·84 (1·29-2·63)      2·13 (1·37-3·30)   
Lymphatic invasion Yes  1·69 (1·10-2·62) 0·018     2·04 (1·23-3·36) 0·0053 
Venous vascular invasion Yes  1·04 (0·74-1·47) 0·81     0·99 (0·64-1·52) 0·96 
Sidedness Right        1·09 (0·70-1·69) 0·71 




Table S10: Harrell's concordance index (95% CI) between cancer-specific survival 
and the DoMore-v1-CRC or Inception v3 score, or one of their constituents 
 
Variable Test cohort Validation cohort 
DoMore-v1-CRC score on Aperio AT2 0·695 (0·659-0·726) 0·674 (0·624-0·719) 
DoMore v1 10x ensemble score on Aperio AT2 0·691 (0·654-0·722) 0·677 (0·627-0·722) 
DoMore v1 40x ensemble score on Aperio AT2 0·690 (0·656-0·721) 0·664 (0·615-0·711) 
Inception v3 score on Aperio AT2 0·679 (0·642-0·712) 0·654 (0·605-0·700) 
Inception v3 10x ensemble score on Aperio AT2 0·663 (0·626-0·698) 0·663 (0·615-0·709) 
Inception v3 40x ensemble score on Aperio AT2 0·674 (0·641-0·707) 0·628 (0·578-0·676) 
DoMore-v1-CRC score on NanoZoomer XR 0·692 (0·656-0·723) 0·674 (0·624-0·718) 
DoMore v1 10x ensemble score on NanoZoomer XR 0·689 (0·652-0·720) 0·678 (0·628-0·722) 
DoMore v1 40x ensemble score on NanoZoomer XR 0·683 (0·649-0·715) 0·659 (0·610-0·704) 
Inception v3 score on NanoZoomer XR 0·677 (0·641-0·711) 0·649 (0·598-0·695) 
Inception v3 10x ensemble score on NanoZoomer XR 0·659 (0·621-0·694) 0·651 (0·602-0·696) 




Table S11: Cross-tabulation of DoMore-v1-CRC class evaluated on Aperio AT2 
slide images and histological grade in the test cohort 
 
DoMore-v1-CRC class Well differentiated Moderately differentiated Poorly differentiated 
Good prognosis 101 (76%) 175 (36%) 33 (11%) 
Uncertain 18 (14%) 106 (22%) 36 (12%) 




Table S12: Multivariable cancer-specific survival analyses in the validation cohort; the multivariable model included the 
DoMore-v1-CRC class evaluated on NanoZoomer XR slide images, and established prognostic markers that were 
significant in the corresponding stage-specific univariable analyses in the validation cohort 
 
Variable Group  Stage II and III  Stage II  Stage III 
      HR (95% CI) p   HR (95% CI) p   HR (95% CI) p 
DoMore-v1-CRC    0·0001   0·0021   0·019 
  Good prognosis  ref.   ref.   ref.   
  Uncertain  1·80 (1·05-3·10)   2·78 (0·84-9·25)   1·63 (0·84-3·15)   
  Poor prognosis  2·46 (1·65-3·67)   4·00 (1·74-9·20)   2·07 (1·25-3·44)   
pN stage    <0·0001      <0·0001 
  pN0  ref.         
  pN1  1·89 (1·17-3·04)      ref.   
  pN2  5·51 (3·45-8·79)      3·00 (1·94-4·63)   
pT stage    0·0004      0·0017 
  pT1  n/a      n/a   
  pT2  1·92 (0·92-3·99)      1·53 (0·58-4·01)   
  pT3  ref.      ref.   
  pT4  2·00 (1·41-2·85)      2·36 (1·53-3·64)   
Lymphatic invasion Yes  1·68 (1·09-2·60) 0·019     2·03 (1·23-3·34) 0·0056 
Venous vascular invasion Yes  1·11 (0·78-1·56) 0·57     1·05 (0·68-1·62) 0·83 
Sidedness Right        1·15 (0·74-1·78) 0·54 




Table S13: Multivariable cancer-specific survival analyses in the validation cohort; the multivariable model included the 
10x ensemble class of the DoMore v1 network evaluated on NanoZoomer XR slide images, and established prognostic 
markers that were significant in the corresponding stage-specific univariable analyses in the validation cohort 
 
Variable Group  Stage II and III  Stage II  Stage III 
      HR (95% CI) p   HR (95% CI) p   HR (95% CI) p 
10x ensemble class Poor prognosis  2·56 (1·77-3·70) <0·0001  3·89 (1·78-8·49) 0·0002  2·17 (1·37-3·44) 0·0009 
pN stage    <0·0001      <0·0001 
  pN0  ref.         
  pN1  1·88 (1·17-3·03)      ref·   
  pN2  5·70 (3·58-9·08)      3·11 (2·02-4·80)   
pT stage    0·0020      0·0025 
  pT1  n/a      n/a   
  pT2  1·86 (0·90-3·86)      1·51 (0·58-3·95)   
  pT3  ref.      ref.   
  pT4  1·96 (1·38-2·79)      2·30 (1·49-3·55)   
Lymphatic invasion Yes  1·66 (1·07-2·56) 0·023     2·02 (1·22-3·33) 0·0060 
Venous vascular invasion Yes  1·05 (0·74-1·49) 0·77     0·99 (0·64-1·53) 0·97 
Sidedness Right        1·14 (0·74-1·77) 0·54 




Table S14: Multivariable cancer-specific survival analyses in the validation cohort; the multivariable model included the 
40x ensemble class of the DoMore v1 network evaluated on NanoZoomer XR slide images, and established prognostic 
markers that were significant in the corresponding stage-specific univariable analyses in the validation cohort 
 
Variable Group  Stage II and III  Stage II  Stage III 
      HR (95% CI) p   HR (95% CI) p   HR (95% CI) p 
40x ensemble class Poor prognosis  1·75 (1·22-2·49) 0·0021  2·87 (1·37-6·04) 0·0035  1·50 (0·96-2·36) 0·075 
pN stage    <0·0001      <0·0001 
  pN0  ref.         
  pN1  1·95 (1·21-3·14)      ref.   
  pN2  5·77 (3·62-9·19)      3·05 (1·98-4·70)   
pT stage    0·0004      0·0005 
  pT1  n/a      n/a   
  pT2  1·74 (0·84-3·61)      1·43 (0·55-3·73)   
  pT3  ref.      ref.   
  pT4  2·14 (1·50-3·04)      2·51 (1·63-3·86)   
Lymphatic invasion Yes  1·70 (1·10-2·63) 0·016     2·03 (1·23-3·34) 0·0056 
Venous vascular invasion Yes  1·17 (0·83-1·64) 0·37     1·11 (0·72-1·69) 0·64 
Sidedness Right        1·17 (0·76-1·80) 0·49 




Table S15: Multivariable cancer-specific survival analyses in the validation cohort; the multivariable model included the 
average of the two DoMore v1 ensemble scores evaluated on NanoZoomer XR slide images, and established prognostic 
markers that were significant in the corresponding stage-specific univariable analyses in the validation cohort 
 
Variable Group  Stage II and III  Stage II  Stage III 
      HR (95% CI) p   HR (95% CI) p   HR (95% CI) p 
DoMore-v1-CRC score 25% increment  2·05 (1·57-2·68) <0·0001  2·64 (1·54-4·50) 0·0004  1·81 (1·29-2·53) 0·0006 
pN stage    <0·0001      <0·0001 
  pN0  ref.         
  pN1  1·81 (1·12-2·91)      ref.   
  pN2  5·58 (3·51-8·87)      3·22 (2·10-4·93)   
pT stage    0·0043      0·0018 
  pT1  n/a      n/a   
  pT2  2·07 (0·99-4·30)      1·66 (0·63-4·39)   
  pT3  ref.      ref.   
  pT4  1·85 (1·30-2·65)      2·20 (1·42-3·41)   
Lymphatic invasion Yes  1·66 (1·08-2·57) 0·022     2·04 (1·24-3·35) 0·0052 
Venous vascular invasion Yes  1·06 (0·75-1·50) 0·73     1·02 (0·66-1·56) 0·95 
Sidedness Right        1·11 (0·72-1·73) 0·63 




Table S16: Multivariable cancer-specific survival analyses in the validation cohort; the multivariable model included the 
10x ensemble score of the DoMore v1 network evaluated on NanoZoomer XR slide images, and established prognostic 
markers that were significant in the corresponding stage-specific univariable analyses in the validation cohort 
 
Variable Group  Stage II and III  Stage II  Stage III 
      HR (95% CI) p   HR (95% CI) p   HR (95% CI) p 
10x ensemble score 25% increment  1·85 (1·49-2·30) <0·0001  2·26 (1·46-3·50) 0·0003  1·66 (1·26-2·18) 0·0003 
pN stage    <0·0001      <0·0001 
  pN0  ref.         
  pN1  1·77 (1·10-2·85)      ref.   
  pN2  5·58 (3·51-8·86)      3·29 (2·14-5·04)   
pT stage    0·0021      0·0070 
  pT1  n/a      n/a   
  pT2  2·09 (1·01-4·36)      1·69 (0·64-4·46)   
  pT3  ref.      ref.   
  pT4  1·81 (1·26-2·59)      2·17 (1·40-3·36)   
Lymphatic invasion Yes  1·66 (1·07-2·56) 0·023     2·02 (1·22-3·32) 0·0058 
Venous vascular invasion Yes  1·06 (0·75-1·50) 0·73     1·01 (0·66-1·56) 0·95 
Sidedness Right        1·11 (0·72-1·72) 0·64 




Table S17: Multivariable cancer-specific survival analyses in the validation cohort; the multivariable model included the 
40x ensemble score of the DoMore v1 network evaluated on NanoZoomer XR slide images, and established prognostic 
markers that were significant in the corresponding stage-specific univariable analyses in the validation cohort 
 
Variable Group  Stage II and III  Stage II  Stage III 
      HR (95% CI) p   HR (95% CI) p   HR (95% CI) p 
40x ensemble score 25% increment  2·11 (1·53-2·90) <0·0001  2·93 (1·52-5·67) 0·0014  1·88 (1·25-2·82) 0·0022 
pN stage    <0·0001      <0·0001 
  pN0  ref.         
  pN1  1·90 (1·18-3·05)      ref.   
  pN2  5·71 (3·59-9·06)      3·13 (2·04-4·80)   
pT stage    0·0018      0·0009 
  pT1  n/a      n/a   
  pT2  1·92 (0·92-3·98)      1·58 (0·60-4·16)   
  pT3  ref.      ref.   
  pT4  1·97 (1·38-2·80)      2·30 (1·49-3·55)   
Lymphatic invasion Yes  1·69 (1·09-2·60) 0·019     2·06 (1·25-3·40) 0·0045 
Venous vascular invasion Yes  1·09 (0·77-1·53) 0·64     1·03 (0·67-1·58) 0·89 
Sidedness Right        1·13 (0·73-1·76) 0·57 




Table S18: Associations between the DoMore-v1-CRC class evaluated on NanoZoomer XR slide images 










prognosis Spearman's correlation 
    (N=596) (N=130) (N=393) ρ (95% CI) p 
Median age at randomisation (IQR), years 64 (57-71) 67 (60-73) 66 (60-71) 0·09 (0·03 to 0·14) 0·0042 
Age at randomisation, years    0·05 (-0·01 to 0·11) 0·092 
  ≤72  494 (83%) 93 (72%) 312 (79%)    
  >72  102 (17%) 37 (28%) 81 (21%)    
Sex     -0·02 (-0·08 to 0·03) 0·42 
  Female 245 (41%) 61 (47%) 170 (43%)    
  Male 351 (59%) 69 (53%) 223 (57%)    
Stage     0·03 (-0·03 to 0·09) 0·34 
  II 222 (37%) 42 (32%) 136 (35%)    
  III 374 (63%) 88 (68%) 257 (65%)    
Stage with substage     0·15 (0·09 to 0·21) <0·0001 
  IIA 123 (22%) 21 (16%) 48 (13%)    
  IIB 91 (16%) 20 (16%) 81 (21%)    
  IIIA 58 (10%) 5 (4%) 12 (3%)    
  IIIB 233 (41%) 51 (40%) 144 (38%)    
  IIIC 59 (10%) 31 (24%) 93 (25%)    
pN stage     0·11 (0·05 to 0·16) 0·0004 
  pN0 222 (39%) 42 (33%) 136 (35%)    
  pN1 294 (51%) 56 (43%) 157 (41%)    
  pN2 59 (10%) 31 (24%) 93 (24%)    
pT stage     0·23 (0·18 to 0·29) <0·0001 
  pT1 13 (2%) 2 (2%) 2 (1%)    
  pT2 55 (10%) 4 (3%) 11 (3%)    
  pT3 338 (60%) 69 (54%) 175 (46%)    
  pT4 160 (28%) 52 (41%) 190 (50%)    
Lymphatic invasion     0·01 (-0·05 to 0·07) 0·64 
  No 503 (90%) 114 (93%) 331 (89%)    
  Yes 56 (10%) 9 (7%) 42 (11%)    
Venous vascular invasion     0·08 (0·02 to 0·14) 0·0074 
  No 354 (63%) 73 (59%) 205 (54%)    
  Yes 208 (37%) 51 (41%) 173 (46%)    
Histological grade     0·14 (0·08 to 0·20) <0·0001 
  1 24 (4%) 8 (7%) 12 (3%)    
  2 477 (85%) 94 (77%) 274 (73%)    
  3 61 (11%) 20 (16%) 87 (23%)    
Location     0·11 (0·05 to 0·17) 0·0002 
  Rectum 97 (17%) 19 (15%) 48 (13%)    
  Distal colon 254 (45%) 54 (43%) 142 (37%)    
  Proximal colon 210 (37%) 52 (42%) 190 (50%)    
Sidedness     0·12 (0·06 to 0·17) 0·0002 
  Left 351 (63%) 73 (58%) 190 (50%)    
  Right 210 (37%) 52 (42%) 190 (50%)    
KRAS     -0·08 (-0·14 to -0·02) 0·0084 
  Wild-type 342 (64%) 77 (66%) 252 (72%)    
  Mutated 195 (36%) 40 (34%) 96 (28%)    
BRAF     0·21 (0·15 to 0·27) <0·0001 
  Wild-type 502 (93%) 96 (83%) 277 (78%)    
  Mutated 36 (7%) 19 (17%) 78 (22%)    
Microsatellite instability     -0·10 (-0·16 to -0·04) 0·0016 
  Yes 53 (9%) 21 (17%) 58 (16%)    
  No 511 (91%) 101 (83%) 304 (84%)    
Median follow-up time (IQR), years 4·8 (3·8-5·1) 4·8 (3·1-5·2) 4·1 (3·1-5·1) -0·12 (-0·18 to -0·06) 0·0001 




Table S19: Cross-tabulation of DoMore-v1-CRC class evaluated on NanoZoomer 
XR slide images and histological grade in the test cohort 
 
DoMore-v1-CRC class Well differentiated Moderately differentiated Poorly differentiated 
Good prognosis 94 (70%) 180 (37%) 33 (11%) 
Uncertain 20 (15%) 77 (16%) 38 (13%) 




Figure S1: log-log plots of cancer-specific survival by DoMore-v1-CRC class evaluated on Aperio AT2 
slide images in the validation cohort (comparable to figure 2) 
 
A   All patients (related to the primary analysis) 
 
B   All patients (five categories) 
 
 
C   Stage II and pN0 (related to a secondary analysis) 
 
 
D   Stage III (related to a secondary analysis) 
 
E   pN1 
 
F   pN2 
 
 
The pre-defined DoMore-v1-CRC classifier was evaluated in Panels A, C, D, E, and F. The DoMore-v1-CRC 




Figure S2: Kaplan-Meier analysis of cancer-specific survival by the constituents of the DoMore-v1-CRC 
class evaluated on Aperio AT2 slide images in the validation cohort 
 
A   10x ensemble classifier (secondary analysis) 
 





Figure S3: Kaplan-Meier analysis of cancer-specific survival by the class of a DoMore v1 10x individual 
model evaluated on Aperio AT2 slide images in the validation cohort 
 
A   Run 1 
 
B   Run 2 
 
C   Run 3 
 
D   Run 4 
 




For each DoMore v1 10x individual model, the score was dichotomised using the same threshold as used for the 




Figure S4: Kaplan-Meier analysis of cancer-specific survival by the class of a DoMore v1 40x individual 
model evaluated on Aperio AT2 slide images in the validation cohort 
 
A   Run 1 
 
B   Run 2 
 
C   Run 3 
 
D   Run 4 
 




For each DoMore v1 40x individual model, the score was dichotomised using the same threshold as used for the 




Figure S5: Cancer-specific survival against DoMore-v1-CRC score evaluated on Aperio AT2 slide images 
 
A   Test cohort 
 
B   Validation cohort 
 
 
The probability of cancer-specific survival was estimated for scores 0, 0·01, and so on up to 1, as the proportion 
of cancer-specific deaths among the 20 patients with nearest score, and the corresponding 95% confidence 
intervals (CIs) were computed as the bias-corrected and accelerated bootstrap CIs. The estimated probabilities 





Figure S6: Receiver operating characteristic (ROC) plots of the DoMore-v1-CRC score and its 
constituents evaluated on Aperio AT2 slide images from patients with distinct outcome  
 
A   DoMore-v1-CRC score, test cohort 
 
B   DoMore-v1-CRC score, validation cohort 
 
C   10x ensemble score, test cohort 
 
D   10x ensemble score, validation cohort 
 
E   40x ensemble score, test cohort 
 
F   40x ensemble score, validation cohort 
 
 
The associated areas under the curves (AUCs) are given with 95% confidence intervals (CIs). Distinct outcome 
in the test cohort was defined as in the training cohort, and similarly for the validation cohort; aged less than 85 
years at randomisation and either more than 6 years follow-up after randomisation without record of recurrence 
or cancer-specific death, or suffered cancer-specific death between 100 days (inclusive) and 2·5 years 
(exclusive) after randomisation. 120 patients in the test cohort had good outcome and 157 had poor outcome, 




Figure S7: Kaplan-Meier analysis of cancer-specific survival by DoMore-v1-CRC class evaluated on 
Aperio AT2 slide images in each substage of the validation cohort 
 
A   Stage IIA 
 
B   Stage IIB 
 
C   Stage IIIA 
 
D   Stage IIIB 
 




The substages were defined with respect to pTNM stage; stage IIA was T3, N0, M0, stage IIB was T4, N0, M0, 





Figure S8: Kaplan-Meier analysis of cancer-specific survival by DoMore-v1-CRC class evaluated on 
Aperio AT2 slide images in pT stages of the validation cohort 
 
A   pT1-3 
 





Figure S9: Kaplan-Meier analysis of cancer-specific survival by DoMore-v1-CRC class evaluated on 
Aperio AT2 slide images in patients with moderately differentiated tumours, i.e. histological grade 2 
 
A   Test cohort 
 





Figure S10: Kaplan-Meier analysis of cancer-specific survival by the Inception v3 classifier and its 
constituents evaluated on Aperio AT2 slide images in the validation cohort 
 
A   Inception v3 classifier (secondary analysis) 
 










Figure S11: Receiver operating characteristic (ROC) plots of the Inception v3 score and its constituents 
evaluated on Aperio AT2 slide images from patients with distinct outcome  
 
A   Inception v3 score, test cohort 
 
B   Inception v3 score, validation cohort 
 
C   10x ensemble score, test cohort 
 
D   10x ensemble score, validation cohort 
 
E   40x ensemble score, test cohort 
 
F   40x ensemble score, validation cohort 
 
 
The associated areas under the curves (AUCs) are given with 95% confidence intervals (CIs). Distinct outcome 
in the test cohort was defined as in the training cohort, and similarly for the validation cohort; aged less than 85 
years at randomisation and either more than 6 years follow-up after randomisation without record of recurrence 
or cancer-specific death, or suffered cancer-specific death between 100 days (inclusive) and 2·5 years 
(exclusive) after randomisation. 120 patients in the test cohort had good outcome and 157 had poor outcome, 




Figure S12: Kaplan-Meier analysis of cancer-specific survival by DoMore-v1-CRC class evaluated on 
Aperio AT2 slide images in the test cohort 
 
A   All patients 
 
B   All patients (five categories) 
 
C   Stage II 
 
D   Stage III 
 
 
The pre-defined DoMore-v1-CRC classifier was evaluated in Panels A, C, and D. The DoMore-v1-CRC 




Figure S13: Scatter plot of the DoMore-v1-CRC score and its constituents evaluated on NanoZoomer XR 
vs. Aperio AT2 slide images in the validation cohort 
 
A   DoMore-v1-CRC score 
 
B   10x ensemble score 
 




Pearson correlation coefficient was 0·956 (95% CI, 0·951-0·961; p<0·0001) for the DoMore-v1-CRC score, 
0·954 (95% CI, 0·948-0·959; p<0·0001) for the 10x ensemble score of the DoMore v1 network, and 0·944 (95% 




Figure S14: Kaplan-Meier analysis of cancer-specific survival by DoMore-v1-CRC class evaluated on 
NanoZoomer XR slide images in the validation cohort 
 
A   All patients (primary analysis) 
 
B   All patients (five categories) 
 
 
C   Stage II and pN0 (secondary analysis) 
 
 
D   Stage III (secondary analysis) 
 
E   pN1 
 
F   pN2 
 
 
The pre-defined DoMore-v1-CRC classifier was evaluated in Panels A, C, D, E, and F. The DoMore-v1-CRC 




Figure S15: log-log plots of cancer-specific survival by DoMore-v1-CRC class evaluated on NanoZoomer 
XR slide images in the validation cohort (comparable to figure S10) 
 
A   All patients (related to the primary analysis) 
 
B   All patients (five categories) 
 
 
C   Stage II and pN0 (related to a secondary analysis) 
 
 
D   Stage III (related to a secondary analysis) 
 
E   pN1 
 
F   pN2 
 
 
The pre-defined DoMore-v1-CRC classifier was evaluated in Panels A, C, D, E, and F. The DoMore-v1-CRC 




Figure S16: Kaplan-Meier analysis of cancer-specific survival by the constituents of the DoMore-v1-CRC 
class evaluated on NanoZoomer XR slide images in the validation cohort 
 
A   10x ensemble classifier (secondary analysis) 
 





Figure S17: Kaplan-Meier analysis of cancer-specific survival by the class of a DoMore v1 10x individual 
model evaluated on NanoZoomer XR slide images in the validation cohort 
 
A   Run 1 
 
B   Run 2 
 
C   Run 3 
 
D   Run 4 
 




For each DoMore v1 10x individual model, the score was dichotomised using the same threshold as used for the 




Figure S18: Kaplan-Meier analysis of cancer-specific survival by the class of a DoMore v1 40x individual 
model evaluated on NanoZoomer XR slide images in the validation cohort 
 
A   Run 1 
 
B   Run 2 
 
C   Run 3 
 
D   Run 4 
 




For each DoMore v1 40x individual model, the score was dichotomised using the same threshold as used for the 




Figure S19: Cancer-specific survival against DoMore-v1-CRC score evaluated on NanoZoomer XR slide 
images 
 
A   Test cohort 
 
B   Validation cohort 
 
 
The probability of cancer-specific survival was estimated for scores 0, 0·01, and so on up to 1, as the proportion 
of cancer-specific deaths among the 20 patients with nearest score, and the corresponding 95% confidence 
intervals (CIs) were computed as the bias-corrected and accelerated bootstrap CIs. The estimated probabilities 





Figure S20: Receiver operating characteristic (ROC) plots of the DoMore-v1-CRC score and its 
constituents evaluated on NanoZoomer XR slide images from patients with distinct outcome 
 
A   DoMore-v1-CRC score, test cohort 
 
B   DoMore-v1-CRC score, validation cohort 
 
C   10x ensemble score, test cohort 
 
D   10x ensemble score, validation cohort 
 
E   40x ensemble score, test cohort 
 
F   40x ensemble score, validation cohort 
 
 
The associated areas under the curves (AUCs) are given with 95% confidence intervals (CIs). Distinct outcome 
in the test cohort was defined as in the training cohort, and similarly for the validation cohort; aged less than 85 
years at randomisation and either more than 6 years follow-up after randomisation without record of recurrence 
or cancer-specific death, or suffered cancer-specific death between 100 days (inclusive) and 2·5 years 
(exclusive) after randomisation. 120 patients in the test cohort had good outcome and 157 had poor outcome, 




Figure S21: Kaplan-Meier analysis of cancer-specific survival by DoMore-v1-CRC class evaluated on 
NanoZoomer XR slide images in each substage of the validation cohort 
 
A   Stage IIA 
 
B   Stage IIB 
 
C   Stage IIIA 
 
D   Stage IIIB 
 




The substages were defined with respect to pTNM stage; stage IIA was T3, N0, M0, stage IIB was T4, N0, M0, 





Figure S22: Kaplan-Meier analysis of cancer-specific survival by DoMore-v1-CRC class evaluated on 
NanoZoomer XR slide images in pT stages of the validation cohort 
 
A   pT1-3 
 





Figure S23: Kaplan-Meier analysis of cancer-specific survival by DoMore-v1-CRC class evaluated on 
NanoZoomer XR slide images in patients with moderately differentiated tumours, i.e. histological grade 2 
 
A   Test cohort 
 





Figure S24: Kaplan-Meier analysis of cancer-specific survival by the Inception v3 classifier and its 
constituents evaluated on NanoZoomer XR slide images in the validation cohort 
 
A   Inception v3 classifier (secondary analysis) 
 
B   10x ensemble classifier (secondary analysis) 
 
 






Figure S25: Receiver operating characteristic (ROC) plots of the Inception v3 score and its constituents 
evaluated on NanoZoomer XR slide images from patients with distinct outcome  
 
A   Inception v3 score, test cohort 
 
B   Inception v3 score, validation cohort 
 
C   10x ensemble score, test cohort 
 
D   10x ensemble score, validation cohort 
 
E   40x ensemble score, test cohort 
 
F   40x ensemble score, validation cohort 
 
 
The associated areas under the curves (AUCs) are given with 95% confidence intervals (CIs). Distinct outcome 
in the test cohort was defined as in the training cohort, and similarly for the validation cohort; aged less than 85 
years at randomisation and either more than 6 years follow-up after randomisation without record of recurrence 
or cancer-specific death, or suffered cancer-specific death between 100 days (inclusive) and 2·5 years 
(exclusive) after randomisation. 120 patients in the test cohort had good outcome and 157 had poor outcome, 




Figure S26: Kaplan-Meier analysis of cancer-specific survival by DoMore-v1-CRC class evaluated on 
NanoZoomer XR slide images in the test cohort 
 
A   All patients 
 
B   All patients (five categories) 
 
C   Stage II 
 
D   Stage III 
 
 
The pre-defined DoMore-v1-CRC classifier was evaluated in Panels A, C, and D. The DoMore-v1-CRC 
classifier variant with five categories was evaluated in Panel B. 
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External evaluation of a deep learning model for prediction of cancer-specific survival 
from colorectal cancer tissue sections 
 
1 Status at last amended 
This protocol was last modified on 18
th
 of March 2019, prior to all investigations that could reveal associations 
between slides and clinical outcome in the QUASAR 2 cohort. At that time the slides in the QUASAR 2 cohort 
had been scanned, segmented and tiled blinded to the clinical outcome, i.e. the recorded cancer-specific survival. 
 
2 Training cohorts 
Four training cohorts were utilised in this study. These were the Ahus cohort, the Aker cohort, the Gloucester 
cohort and the VICTOR cohort that are described in the following subsections. Patients in the training cohorts 
were labelled as distinct or non-distinct prognosis depending on age at surgery and follow-up data. The distinct 
prognosis patients are comprised of patients defined as good prognosis and patients defined as poor prognosis. A 
patient was defined as good prognosis if aged less than 85 years at surgery, had more than 6 years follow-up 
after surgery, had no record of cancer-specific death and no record of recurrence. The availability of recurrence 
data varied between the cohorts and was particularly limited for the Gloucester cohort. For the Ahus cohort, 
good prognosis patients were required to have no record of metastasis (records of local recurrences were not 
available), while no record of local or metastatic recurrence were required for Aker, Gloucester and VICTOR 
patients. A patient was defined as poor prognosis if aged less than 85 years at surgery and suffered cancer-
specific death between 100 days (inclusive) and 2.5 years (exclusive) after surgery. Patients not satisfying the 
criteria for either good or poor prognosis were defined as non-distinct prognosis. 
 
2.1 Ahus cohort 
From a consecutive series of 219 patients with colonic adenocarcinoma treated between 1988 and 2000 at 
Akershus University Hospital, Norway
1
, 172 patients had stage I, II or III disease and accessible formalin-fixed, 
paraffin-embedded (FFPE) tissue blocks. A 3 µm section of each FFPE tumour tissue block was stained with 
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Protocol Fig. 1 | A diagram specifying inclusions and exclusions of patients, slides and slide images from the Ahus cohort, and 
the prognosis of the included patients. CSS, cancer-specific survival; CSD, cancer-specific death. 
 
haematoxylin and eosin (H&E) and prepared as tissue slides by laboratory personnel at the Institute for Cancer 
Genetics and Informatics (ICGI), Oslo University Hospital, Norway. A pathologist ascertained whether there 
was tumour in each tissue section; the 12 patients without tumour slide were excluded (Protocol Fig. 1). The 
tumour tissue slides were scanned using two scanners, an Aperio AT2 (Leica Biosystems, Germany) and a 
NanoZoomer XR (Hamamatsu Photonics, Japan). The scans were read using the Python interface (version 1.1.1) 
of OpenSlide 3.4.1, available at https://openslide.org/. An automatic segmentation method (see section 3) was 
applied to identify tumour in the 320 slide images, and each slide image were partitioned into multiple non-
overlapping regions called tiles using two resolution referred to as 40x and 10x (see section 4). The 160 included 
patients with tiles within the tumour segmentation were defined as the Ahus cohort; Protocol Fig. 1 specifies the 
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2.2 Aker cohort 
One slide from each of the 578 stage I, II or III patients treated between 1993 and 2003 for primary colorectal 
cancer at Aker University Hospital, Norway, and analysed by Danielsen and colleagues
2
 were processed in the 
same manner as for the Ahus cohort. Three slides had damaged cover glass and could therefore not be scanned 
by the NanoZoomer XR scanner, and the automatic segmentation method identified no tumour for three Aperio 




Protocol Fig. 2 | A diagram specifying inclusions and exclusions of patients, slides and slide images from the Aker cohort, and 
the prognosis of the included patients. CSS, cancer-specific survival; CSD, cancer-specific death. 
 
2.3 Gloucester cohort 
The Gloucester Colorectal Cancer Study recruited 1,036 patients between 1988 and 1996, of which 19 were 
excluded because of synchronous cancer (Protocol Fig. 3)
3,4
. The remaining 1,017 patients were processed in the 
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same manner as for the Ahus cohort, resulting in 969 patients with Aperio AT2 segmentations and 967 patients 
with NanoZoomer XR segmentations (Protocol Fig. 3). These patients constituted the Gloucester cohort, but one 
of them was excluded from the Aperio AT2 10x tile set because of no tile within the tumour segmentation 
(Protocol Fig. 3). 
 
 
Protocol Fig. 3 | A diagram specifying inclusions and exclusions of patients, slides and slide images from the Gloucester 
cohort, and the prognosis of the included patients. CSS, cancer-specific survival; CSD, cancer-specific death. 
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2.4 VICTOR cohort 
The VICTOR trial randomised stage II and III colorectal cancer patients to receive rofecoxib or placebo after 
primary treatment in order to examine cardiovascular adverse events
5,6
. An H&E-stained 3 µm section from a 
FFPE tissue block was retrieved for 795 of the patients recruited between 2002 and 2004, some of which were 
sectioned at ICGI and some of which were sectioned elsewhere. The sections were processed in the same manner 
as for the Ahus cohort. The VICTOR cohort consisted of 767 patients with Aperio AT2 40x tiles, 764 patients 
with Aperio AT2 10x tiles, 761 patients with NanoZoomer XR 40x tiles and 756 patients with NanoZoomer XR 
10x tiles (Protocol Fig. 4). 
 
Protocol Fig. 4 | A diagram specifying inclusions and exclusions of patients, slides and slide images from the VICTOR cohort, 
and the prognosis of the included patients. CSS, cancer-specific survival; CSD, cancer-specific death. 
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3 Segmentation 
The segmentation method consists of a method to produce probability maps from input images, and a different 
method to create an image partitioned into foreground and background regions based on the input image and the 
corresponding probability map. The probability maps are generated by a segmentation network based on the 
DeepLab network
7




The method was initially trained on 1077 images with corresponding annotations from the Aker cohort (670 
images) and VICTOR cohort (407 images). The images were obtained from slides scanned with a NanoZoomer 
(Hamamatsu Photonics, Japan) scanner, and the annotations was hand-drawn by a pathologist. This trained 
method was then applied on images from the Aker cohort, the Ahus cohort, and the Gloucester cohort. The 
resulting segmentations was verified by a pathologist, which corrected the ones that was unsatisfactory. This set 
of images with corresponding (possibly corrected) masks constitutes the development dataset of the image 
segmentation method. 
 
From the development dataset of 1717 patients, 25% (429 patients) was drawn uniformly at random to form a 
tuning set, and the remaining 1288 patients comprised the training set. In the training set there was 358 patients 
with a cancer-specific event, and 930 images patients without. In the tuning set there was 128 images patients 
with a cancer-specific event, and 301 patients without. Slides from patients in the segmentation development set 
was scanned with both an Aperio AT2 scanner and a NanoZoomer XR scanner. The development set in the 
segmentation task is therefore comprised of 3430 scans (4 scans from the NanoZoomer XR scanner was 
missing), with 2573 in the training set, and 857 in the tuning set. 
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Protocol Fig. 5 | Illustration of the segmentation network architecture. Each layer is represented by name, output height, output 
width, and number of output channels. Progression is downwards from the input image at the top to the prediction output at the 
bottom. 
 
Each scan is digitally resized to a size corresponding to a 2.5x resolution (see section 4), and stored as a PNG 
image. Each image is then resized to fit within a frame of 1600x1600 pixels with a Catmull-Rum cubic filter. 
This is done by resizing the image while preserving the aspect ratio until its largest dimension (height or width) 
is 1600 pixels. A new image is then formed by padding the resized image along its shortest dimension on each 
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side until it also is 1600 pixels. The centre of the resized image aligns with the centre of the padded image, and 
the padded image is used further. 
 
The segmentation network was trained with 100,000 update steps (training iterations), and each update step uses 
16 images (this collection is called a mini-batch) distributed on 4 GPUs. Every image in the development dataset 
is used once before one is used twice, which means that each image is seen on about 622 times during training 
(one progression through a dataset is termed an epoch). At each epoch, the same image is used once, but with 
slight variations each time. First, a section of 641x641 pixels is cropped at a random location within the image. 
Then, a set of orientation distortions are applied in the following order 
1. With a probability of 50%, flip the image horizontally (mirror along its horizontal axis). 
2. With a probability of 50%, flip the image vertically (mirrored along its vertical axis). 
3. With a probability of 50%, rotate the image once with one of the following degrees: 0, 90, 180, 270. 
Finally, the image is centred around its mean and standard deviation (see 
https://www.tensorflow.org/versions/r1.10/api_docs/python/tf/image/per_image_standardization). The resulting 
image is fed into the segmentation network as an RGB image. 
 
The trainable parameters are initialized using a Xavier weight initialization scheme, and updated using a 
standard stochastic gradient descent optimization method
9
. The step length in the optimization is initialized to 
0.05, and decreased by a factor of 0.1 at iteration 96488 (about 600 training epochs). 
 
Applying the trained network on an image yields a probability map with the same spatial shape as the image. 
This probability map is a one-channel grayscale image with intensity values in 0, 1, …, 255. The method assigns 
high values to regions it finds probable depicting cancerous tissue. 
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For each image, we create additional versions of the image by rotating and flipping the original image, before we 
apply the trained network on all the different versions. There are 8 versions, and they are obtained from the 
original image by the following operations 
1. Do nothing (this is the original image) 
2. Flip the image around its horizontal axis 
3. Flip the image around its vertical axis 
4. Rotate the image 90 degrees clockwise 
5. Rotate the image 180 degrees clockwise 
6. Rotate the image 270 degrees clockwise 
7. Rotate the image 90 degrees clockwise and flip the result around its horizontal axis 
8. Rotate the image 270 degrees clockwise and flip the result around its horizontal axis 
The resulting probability maps are then restored to their original orientation, and an average image of all the 
different versions is computed and used further in the process. 
 
At inference, the trained network is applied on one image at the time (i.e. with a batch-size of one), and contrary 
to the training phase, neither cropping nor orientation distortion is applied. However, it is important that every 
image is centred around its mean and standard deviation as was done in training. The network was implemented 
and run in Python 3.5 (https://www.python.org) using TensorFlow 1.10 (https://www.tensorflow.org). 
 
Segmentation of the probability maps was performed using the Python library pydensecrf v1.0rc3 
(https://github.com/lucasb-eyer/pydensecrf). The model used a unary potential (the probability map), a gaussian 
pairwise potential (addPairwiseGaussian(sxy=1, compat=1)), and a bilateral pairwise potential 
(addPairwiseBilateral(sxy=30, srgb=3, compat=100)). The result image with float values in (0, 1) is thresholded 
at 0.5 to produce a binary mask, where pixels with value less than 0.5 is labelled as background, and the rest as 
foreground. 
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The resulting segmentation is smoothed with a 5x5 mean filter, before foreground regions connected with a 
eight-neighbourhood with fewer than 20,000 pixels are removed. Background regions fully contained within 
foreground regions are marked as foreground. 
 
The method was applied on the tuning set every 4,000 iterations, and the predicted segmentations was evaluated 
against the reference segmentations. The model that achieved the highest mean bookmakers informedness score 
was then selected as the model to be used in the rest of the experiment. The model at iteration 88,000 achieved 
the highest score of 0.902 (Protocol Fig. 6). 
 
Protocol Fig. 6 | Performance of the segmentation method on the tuning set. The method is evaluated at multiple training 
iterations evenly spaced across the training progression. 
 
4 Tiling 
The region identified as tumour by the segmentation method is not directly suitable as input to a convolutional 
neural network (CNN) because of limited GPU memory in commonly available hardware. We therefore made 
multiple non-overlapping regions of a fixed size, called tiles, from within the region segmented as tumour in 
each slide image. Since the physical area represented by a pixel depends on the scanner
*
, tiles representing the 
                                                          
*
 The physical area represented by a pixel can also depend on the applied scan settings, but this is not an issue 
here as we used the same settings for each of the scanners when scanning the slides in the training and validation 
cohorts. 
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same physical area were created by including slightly different number of pixels in tiles from Aperio AT2 and 
NanoZoomer XR slide images. At maximum resolution, termed 40x, pixels in the Aperio AT2 slide images had a 
physical size of 0.253 µm/pixel both vertically and horizontally, while pixels in the NanoZoomer XR slide 
images had 0.227 µm/pixel both vertically and horizontally. To make 40x tiles, tiles with 486x486 pixels were 
extracted from within the tumour segmentation of Aperio AT2 slide images, while 542x542 pixels were used for 
NanoZoomer XR slide images. Similarly, a tile size of 1942x1942 pixels were used for Aperio AT2 slide images 
and 2166x2166 pixels for NanoZoomer XR slide images to make 10x tiles. Each of these raw tiles was then 
resampled to 512x512 pixels, making the physical area of each pixel similar for both scanners; 0.240x0.240 µm 
for 40x tiles and 0.960x0.960 µm for 10x tiles. 
 
Technically, the tiling was performed by defining a grid of candidate tiles from the top left corner of the slide 
image, including regions outside the tumour segmentation. Candidate tiles for which the four corners and their 
midpoints along the edges were within the boundaries of the segmentation were included. Tiles were extracted 
with OpenSlide from level 0, converted to numpy arrays, resized with OpenCV using the resize() function 
(https://docs.opencv.org/3.4.0/da/d54/group__imgproc__transform.html) with interpolation set to 
cv2.INTER_CUBIC for up-sampling and cv2.INTER_AREA for down-sampling and saved in a lossless format 
(as PNG files). 
 
5 Patient survival prediction methods 
Two neural networks were trained using all patients with distinct prognosis in the training cohorts. Each network 
was trained five times with 40x tiles and another five times with 10x tiles; the resampled tiles with 512x512 
pixels were used in both cases. The applied ground truth (i.e. true outcome) in these supervised classification 
methods was the patient’s distinct prognosis, either good or poor prognosis (as defined in section 2). 
 
5.1 DoMore v1 network 
One network, called DoMore v1 network, is a multiple instance classification method comprised of a 
representation network, a multiple instance pooling function, and a classification network (Protocol Fig. 7). 
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Rather than a single tile, the DoMore v1 network classifies a collection of tiles called a bag, where all tiles 
within a bag originates from the same scan image. Each tile in a bag is applied with the representation network to 
produce a feature representation of the tile (note that within one update step, all tiles uses the same representation 
network with the same parameter values). All tile representations are aggregated and a single value for each class 
is produced by the pooling function. A final classification network is then applied, and predictions are produced. 
These predictions are compared with the ground truth corresponding to the image the bag originates from using a 
loss function. This loss function is optimised using a gradient-based optimisation routine, and at each training 
iteration, the trainable parameters of the network are updated according to this optimisation method. Only a 
randomly selected subset of the tiles in the bag is used to update the network. This asymmetric forward and 
backward propagation reduces the memory footprint of the network, and allows larger bags of tiles during 
training. 
 
The representation network is based on the MobileNet v2 network, and its details is illustrated in Protocol Fig. 
7
10
. The first convolution layer in the representation network uses a 3x3 convolution kernel with a stride of 2. 
The activation function is a ReLU activation function
11
. Inside each inverted bottleneck module, the first 
convolution layer uses a 1x1 convolution kernel with a stride of 1 and a ReLU6 activation function
12
. The depth-
wise separable convolution layer uses a 3x3 convolution kernel. Whenever the spatial size halves in height and 
width, the stride is 2, otherwise it is 1. The activation function is the ReLU6 function. The last convolution layer 
uses a 1x1 convolution kernel with a stride of 1, and an identity activation function. When the number of input 
channels to the inverted bottleneck module is equal to the number of output channels in the same module, the 
input to the first convolution layer within the module is added to the result of the last convolution layer within 
the module. The convolution layer after the inverted bottleneck modules uses a 1x1 convolution with stride 1 and 
the ReLU activation function. All convolution and separable convolution layers described above employ batch 
normalization on the result of the convolution, before the activation function is applied
13
. All kernel weights are 
initialised with Xavier initialization, and no bias parameters are used. The final convolution layer uses a 1x1 
convolution kernel with stride 1. No batch normalization is used in this layer, and the activation is the identity 
function. The rest of the network consists of a noisy-and pooling function followed by a softmax classification, 
following the design of Kraus and colleagues
14
. There is one cross-entropy loss function associated with the 
output of the pooling function, and one cross-entropy loss function associated with the classification output. 
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Protocol Fig. 7 | Illustration of the DoMore v1 network architecture. The left side gives an overview over progression from an 
input bag of tiles to a bag prediction. The right side shows the architecture of the representation network, where each layer is 
represented by name, output height, output width, and number of output channels. 
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The network was trained with a batch size of 32 bags, distributed across 8 GPUs with 4 bags on each GPU. Each 
bag consisted of 64 tiles with size 512x512x3 pixels and with values in 0, 1, …, 255. The number of tiles 
contributing to the gradient computation was 8. For updating the network parameters, an initial step size of 0.001 
was used with the Adam optimisation method
15
. When training on 10x tiles, the learning rate was initially set to 
0.001 and then successively reduced by a factor of 0.1 at iteration 6,000 and again at iteration 12,000 before 
training ceased after iteration 15,000. Twice the number of iterations were utilised to train on 40x tiles, i.e. the 
learning rate started at 0.001 and was successively reduced by a factor of 0.1 at iteration 12,000 and again at 
iteration 24,000 before training ceased after iteration 30,000. 
 
At each step, before entering the network, each tile is distorted and normalised. First, it is randomly cropped to a 
size of 448x448, before the orientation of the tile is distorted. The tile is randomly flipped from left to right 
(around its central vertical axis), then randomly flipped from top to bottom (around its central horizontal axis), 
and finally randomly rotated by either 0°, 90°, 180° or 270°. Then its values are scaled to (0, 1) by casting it to a 
32-bit floating point number before dividing the entire tile by 255.0. The tile is then converted from the RGB 
colour space to the HSV colour space before each channel is scaled with a value uniformly distributed between 
1/1.1 and 1.1. The tile is then converted back to RGB. Finally, the tile is normalised to have zero mean and unit 
norm (see rgb_to_hsv, hsv_to_rgb, per_image_standardization at 
https://www.tensorflow.org/versions/r1.10/api_docs/python/tf/image for more information). At inference, no 
cropping is applied, so the entire tile of size 512x512x3 pixels is evaluated by the network. Also no orientation 
or colour distortions are applied. Before entering the network, each tile is normalised to have zero mean and unit 
norm as in training. The network was implemented and run in Python 3.5 (https://www.python.org) using 
TensorFlow 1.10 (https://www.tensorflow.org). To account for class imbalance in the training set, the minority 
class within a cohort-scanner combination was oversampled such that there was an equal amount of images 
labelled with good prognosis and poor prognosis in every cohort-scanner combination. Within each cohort-
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5.2 Inception v3 network 
The other network, an Inception v3 network
16
, was trained with Keras (2.1.6) using the Tensorflow Docker 
image (tensorflow/tensorflow:1.9.0-gpu-py3). The input image size was 512x512 and the output was two classes 
with the first class being the probability of good prognosis and the second class the probability of poor 
prognosis. A binary cross entropy loss function was used, and it was optimised with keras.optimizers.Adam 
using default arguments, except for initial learning rate which was set to 0.0001. To account for class imbalance 
between tiles from good and poor prognosis, tiles from the minority class were oversampled per cohort prior to 
training and the file paths were saved as a list. Consequently, each cohort contained the same number of included 
tiles with good and poor prognosis, at the expense of potentially including some tiles twice. The list of tiles was 
loaded prior to training and randomly shuffled before a modified version of 
keras.preprocessing.image.ImageDataGenerator was utilised to load batches of images using 16 worker threads. 
The ImageDataGenerator was modified to perform colour distortion by 
1. converting the tile to HSV colour space, 
2. augmenting the hue by adding a random uniformly sampled value between 0.05, 
3. scaling the saturation by a random uniformly sampled value between 1/1.1 and 1.1, 
4. shifting the saturation by a random uniformly sampled value between 0.1, 
5. scaling the value by a random uniformly sampled value between 1/1.1 and 1.1, 
6. shifting the value by a random uniformly sampled value between 0.1, and 
7. converting the tile back to the RGB colour space. 
The tile was then standardised by subtracting the mean colour values and dividing by the standard deviation of 
all tiles used for training, i.e. all tiles of patients with distinct prognosis in the training cohorts. For each training 
iteration, a batch size of 16 tiles was used due to GPU memory constraints. When training on 10x tiles, the 
learning rate was initially set to 0.0001 and then successively halved for each 25,000
nd
 iteration, starting at 
iteration 25,000, before training ceased after iteration 150,000. Twice the number of iterations were utilised to 
train on 40x tiles, i.e. the learning rate started at 0.0001 and was successively halved for each 50,000
nd
 iteration, 
starting at iteration 50,000, before training ceased after iteration 300,000. The network output was the predicted 
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probability of poor prognosis for a tile. The predicted probability of poor prognosis for a patient was computed 
by averaging the predicted probabilities of all tiles for that patient. 
 
6 Individual models 
Training each of the two networks five times for each of the two resolutions resulted in 20 training runs. For 
each of these 20 training runs, 21 models were evaluated on all patients with non-distinct prognosis in the 
training cohorts. The 21 models evaluated for each training run was uniformly distributed from 1/3 of the 
iterations to the training ceased (both ends inclusive). Each 10x model of the DoMore v1 network was evaluated 
at iteration 5,000, 5,500, and so on up to iteration 15,000. Each 40x model of the DoMore v1 network was 
evaluated at iteration 10,000, 11,000, and so on up to iteration 30,000. Each 10x model of the Inception v3 
network was evaluated at iteration 50,000, 55,000, and so on up to iteration 150,000. Each 40x model of the 
Inception v3 network was evaluated at iteration 100,000, 110,000, and so on up to iteration 300,000. 
 
To reduce evaluation time for the 40x models, a random sample of 2,000 40x tiles were selected for each slide 
with more than 2,000 40x tiles. The same tiles were evaluated for all models. To reduce further the evaluation 
time for the 40x models of the DoMore v1 network, patients with more than 50 tiles were evaluated using 50 
tiles at a time, resulting in that tiles ordered after the last multiple of 50 were ignored in these evaluations, i.e. at 
most 49 tiles were ignored for each patient. Note that these speed-ups were only applied during model selection; 
for all applications of the selected models, including the external evaluation described in this protocol, all tiles 
will be evaluated. 
 
The model that maximised Harrell’s concordance index
17
 (c-index) was selected for each training run. The c-
index compared the observed time to cancer-specific death or censoring to a model’s predicted probability of 
poor prognosis for patients with non-distinct prognosis in the training cohorts. The model with largest c-index 
thus appeared to provide most prognostic information in its predicted probabilities when evaluated on non-
distinct prognosis patients in the training cohorts. Protocol Figs. 8-11 show the c-index of all candidate models 
and indicate the selected model for each of the 21 training runs. 













Protocol Fig. 8 | c-index of the 21 candidate 10x models of the DoMore v1 network for patients with non-distinct prognosis in 
the training cohorts. The blue point indicates the selected model, green points indicate models not selected. The c-index of nine 



















Protocol Fig. 9 | c-index of the 21 candidate 40x models of the DoMore v1 network for patients with non-distinct prognosis in 
the training cohorts. The blue point indicates the selected model, green points indicate models not selected. The c-index of nine 

















Protocol Fig. 10 | c-index of the 21 candidate 10x models of the Inception v3 network for patients with non-distinct prognosis in 
the training cohorts. The blue point indicates the selected model, green points indicate models not selected. The c-index of nine 

















Protocol Fig. 11 | c-index of the 21 candidate 40x models of the Inception v3 network for patients with non-distinct prognosis in 
the training cohorts. The blue point indicates the selected model, green points indicate models not selected. The c-index of nine 
models from the first third of the training run is shown as red points for comparison. Subplot a to e show training run 1 to 5. 
 
7 Ensemble models 
An ensemble model was created for each network and resolution by averaging the five selected models’ 
predicted probability of poor prognosis for a patient, resulting in four ensemble models; a 10x and a 40x 
ensemble model of the DoMore v1 network and similarly for the Inception v3 network. To determine a suitable 
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threshold for dichotomising each ensemble model’s predicted probability of poor prognosis, we computed the c-
index of the dichotomised ensemble model prediction for thresholds at 0.01, 0.02, and so on up to and including 
0.99 for patients with non-distinct prognosis in the training cohorts. The threshold obtaining the maximum c-
index was selected for each ensemble model (Protocol Fig. 12). For the 10x ensemble model of the DoMore v1 
network, the predicted outcome was poor prognosis if the ensemble model’s predicted probability of poor 
prognosis was greater than 0.51, otherwise, the predicted probability was less than or equal to 0.51 and the 
predicted outcome was good prognosis. This dichotomous marker was termed the 10x ensemble marker of the 
DoMore v1 network. Similarly, the 40x ensemble marker of the DoMore v1 network was defined using a 
threshold of 0.56, and both the 10x and the 40x ensemble marker of the Inception v3 network was defined using 









Protocol Fig. 12 | c-index of an ensemble model’s predicted probability of poor prognosis thresholded at 0.01, 0.02, and so on 
up to and including 0.99 for patients with non-distinct prognosis in the training cohorts. a,The 10x ensemble model of the 
DoMore v1 network. b,The 40x ensemble model of the DoMore v1 network. c,The 10x ensemble model of the Inception v3 
network. d,The 40x ensemble model of the Inception v3 network. 
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A combined 10x and 40x ensemble model was created for each network by defining patients were the 10x and 
40x ensemble markers predict the same outcome as either predicted good prognosis (if both ensemble markers 
predict good prognosis) or predicted poor prognosis (if both ensemble markers predict poor prognosis), and 
patients where the 10x and 40x ensemble markers predict different outcome as predicted uncertain prognosis. If 
one of the ensemble markers could not be assayed for a patient, e.g. because there was no 10x tiles, then the 
combined 10x and 40x ensemble marker was not defined either, thus such patients was excluded from analyses 
of the combined model. This resulted in two combined 10x and 40x ensemble markers, one for the DoMore v1 
network and one for the Inception v3 network. These 3-grouped variables will be referred to as the DoMore v1 
marker and the Inception v3 marker. 
 
8 QUASAR 2 cohort 
The open-label, randomised, controlled QUASAR 2 trial (ISRCTN registry number ISRCTN45133151) enrolled 
1952 patients with histologically proven stage III or high-risk stage II colorectal cancer between April 2005 and 
October 2010 from 170 hospitals in seven countries (Australia, Austria, Czech Republic, New Zealand, Serbia, 
Slovenia and the UK), of whom 1,941 had assessable data
18
. The trial was designed to investigate whether 
bevacizumab improved disease-free survival after potentially curative surgery of primary tumour. All patients 
received adjuvant chemotherapy in the form of capecitabine, but none received neoadjuvant treatment. No 
significant difference was observed between the treatment arms and the investigators concluded that the addition 




Through encouraging, but not requiring blood samples and tumour samples from primary resections, FFPE tissue 
blocks were collected from 1,251 of the QUASAR 2 trial patients with stage II or III colorectal cancer. These 
patients were representative for the whole trial population in terms of clinical and pathological characteristics
18
. 
Pathologists at the participating hospitals in the trial performed the pathological evaluations. All patients 
provided written informed consent for treatment and the use of tissue samples. The West Midlands Research 
Ethics Committee (no. 04/MRE/11/18) and the Regional Committees for Medical and Health Research Ethics 
(REK) in Norway (no. 2015/1607) approved the study. 
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Tissue blocks from 1,140 patients were received, sectioned and prepared as 3 µm H&E-stained tissue slides by 
laboratory personnel at ICGI (Protocol Fig. 13). A local pathologist blinded to clinical outcome ascertained the 
presence of tumour in each tissue section. Digital images of the 1,132 sections with tumour were acquired using 
the same two scanners as in the training cohorts, i.e. an Aperio AT2 and a NanoZoomer XR. The previously 
developed segmentation model was blindly applied to automatically identify regions with tumour, giving 1,113 
patients with Aperio AT2 segmentations and 1,121 patients with NanoZoomer XR segmentations (Protocol Fig. 
13). The slide images where tiled as in the training cohorts, but no 10x tile could fit inside the automatic tumour 
segmentation for 3 Aperio AT2 segmentations and 2 NanoZoomer XR segmentations (Protocol Fig. 13). The 
QUASAR 2 cohort was defined as the 40x tiles from the Aperio AT2 slide images (available for 1,113 patients), 
the 10x from the Aperio AT2 slide images (available for 1,110 patients), the 40x tiles from the NanoZoomer XR 
slide images (available for 1,121 patients) and the 10x tiles form the NanoZoomer XR slide images (available for 
1,119 patients). 
 
Protocol Fig. 13 | A diagram specifying inclusions and exclusions of patients, slides and slide images from the QUASAR 2 
cohort. 
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The QUASAR 2 cohort is representative for patients eligible for the QUASAR 2 trial. An eligible patient had to 
satisfy all of the following inclusion criteria (originally described by Kerr et al.
18
): 
- Aged 18 years or older. 
- Colorectal adenocarcinoma. 
- Histologically proven R0 M0 stage III or high-risk stage II colorectal cancer, where high-risk was 
defined as the presence of one or more of the following adverse prognostic features: stage T4, 
lymphatic invasion, vascular invasion, peritoneal involvement, poor differentiation and preoperative 
obstruction or perforation of the primary tumour 
- Primary resection between 4 and 10 weeks prior to randomisation. 
- World Health Organisation (WHO) Performance Status 0 or 1. 
- Life expectancy of at least 5 years when taking into account comorbidities, but excluding cancer risk. 




- History of cancer other than treated in-situ carcinoma of the cervix, basal or squamous-cell carcinoma 
or if the disease-free interval after a previous cancer was greater than 10 years. 
- Inflammatory bowel disease and/or active peptic ulcer requiring treatment in the last 2 years. 
- Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome or inability to take 
oral medication. 
- Moderate or severe renal impairment (creatinine clearance <30 mL/min). 
- Any of the following blood abnormalities: 
o Absolute neutrophil count <1.5x109/L. 
o Platelet count <100x109/L. 
o Total bilirubin concentration >1.5 times the upper limit of normal (ULN). 
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o Alanine aminotransferase, aspartate aminotransferase or alkaline phosphatase concentration 
>2.5 times the upper limit of normal (ULN). 
- Proteinuria >500 mg per 24 hours. 
- Previous chemotherapy, immunotherapy or infra-diaphragmatic radiotherapy (including neoadjuvant 
therapy to the rectum) or patients who are expected to require radiotherapy to these sites within the next 
12 months. 
- Use of any investigational drug or agent/procedure within 4 weeks of randomisation. 
- Chronic use of full-dose anticoagulants, high-dose aspirin (>325 mg/day), anti-platelet drugs or known 
bleeding diathesis (low-dose aspirin was allowed). 
- Concomitant treatment with sorivudine or its chemically related analogues. 
- History of uncontrolled seizures, central nervous system disorders or psychiatric precluding informed 
consent or interfering with compliance for oral drug intake. 
- Clinically significant cardiovascular disease, i.e. active or <12 months since e.g. cerebrovascular 
accident, myocardial infarction, unstable angina, New York Heart Association (NYHA) grade II or 
greater congestive heart failure, serious cardiac arrhythmia requiring medication or uncontrolled 
hypertension. 
- Known coagulopathy. 
- Known allergy to Chinese hamster ovary cell proteins or other recombinant human or humanised 
antibodies or to any excipients of bevacizumab formulation. 
- Women who were pregnant or lactating, or premenopausal women not using contraception. 
 
9 Primary analysis 
We predefined a primary analysis of the DoMore v1 marker for each scanner (Aperio AT2 and NanoZoomer 
XR) in the QUASAR 2 cohort. The selected metric for measuring model performance was the hazard ratio (with 
95% confidence interval [CI]) of patients predicted as uncertain prognosis and patients predicted as poor 
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prognosis relative to patients predicted as good prognosis, where the two hazard ratios (and their corresponding 
CIs) will be computed by analysing a Cox proportional hazard model with the DoMore v1 marker as the only 
variable (the DoMore v1 marker will be included as a categorical variable, i.e. the model will consist of the two 
indicator variables for uncertain prognosis and poor prognosis) and cancer-specific survival as endpoint (Efron’s 
method will be used in case of tied events). The selected test for assessing whether the DoMore v1 marker 
predicts cancer-specific survival was the two-tailed Mantel-Cox logrank test using significance level 0.05. Time 
to cancer-specific survival will be computed from date of randomisation to date of cancer-specific death or loss 
to follow-up. The primary analysis is an unbiased evaluation of the DoMore v1 marker’s ability to predict 
cancer-specific survival in the target population of patients that received adjuvant chemotherapy (specifically 
capecitabine) and satisfied the eligibility criteria of the QUASAR 2 trial. 
 
10 Secondary analyses 
The following secondary analyses were planned in advance of all investigations in the QUASAR 2 cohort that 
could reveal associations between the slides and clinical outcome, i.e. the recorded cancer-specific survival: 
- Repeat the primary analysis for the constituents of the DoMore v1 marker, i.e. the two dichotomous 10x 
and 40x ensemble markers of the DoMore v1 network. Note that since these are dichotomous markers, 
there will only be one hazard ratio for each of them, i.e. that of patients predicted as poor prognosis 
relative to patients predicted as good prognosis. 
- Repeat the primary analysis (of the DoMore v1 marker) for stage II and III patients separately. 
- Include the DoMore v1 marker evaluated on Aperio AT2 slide images as a categorical variable (as in 
the primary analysis) in a multivariable model together with relevant markers that is available at the 
time of analysis and is significant in univariable analysis of cancer-specific survival (defined as in the 
primary analysis) in the QUASAR 2 cohort. Analyse the model with the same endpoint definition as in 
the primary analysis. Compute the hazard ratio (with 95% CI) and corresponding P value of patients 
predicted as uncertain prognosis and patients predicted as poor prognosis relative to patients predicted 
as good prognosis using Cox proportional hazard model and Wald Χ2 test when analysing only patients 
with complete data for all variables included in the multivariable model. Current candidate markers are: 
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o Pathological N stage (with categories N0, N1 and N2). Note that this marker incorporates the 
pathological stage, i.e. stage II or stage III. 
o Pathological T stage (with categories 1, 2, 3 and 4). 
o Age at randomisation (continuous on linear scale). 
o Sex (with categories Female and Male). 
o Histological grade (with categories 1, 2 and 3). 
o Location. (with categories Proximal colon, Distal colon and Rectum where Proximal colon 
includes the cecum through the transverse colon and Distal colon includes the left flexure 
through the rectosigmoid flexure). 
o Venous vascular invasion (with categories No and Yes). 
o Lymphatic invasion (with categories No and Yes). 
o MSI (with categories Unstable and Stable). 
o BRAF (if available). 
o KRAS (if available). 
- Repeat the primary analysis for the Inception v3 marker. 
- Repeat the primary analysis for the constituents of the Inception v3 marker, i.e. the two dichotomous 
10x and 40x ensemble markers of the Inception v3 network. Again note that since these are 
dichotomous markers, there will only be one hazard ratio for each of them, i.e. that of patients predicted 
as poor prognosis relative to patients predicted as good prognosis. 
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